WO2009121210A1 - 双链聚乙二醇修饰的生长激素及其制备方法和应用 - Google Patents

双链聚乙二醇修饰的生长激素及其制备方法和应用 Download PDF

Info

Publication number
WO2009121210A1
WO2009121210A1 PCT/CN2008/000674 CN2008000674W WO2009121210A1 WO 2009121210 A1 WO2009121210 A1 WO 2009121210A1 CN 2008000674 W CN2008000674 W CN 2008000674W WO 2009121210 A1 WO2009121210 A1 WO 2009121210A1
Authority
WO
WIPO (PCT)
Prior art keywords
growth hormone
polyethylene glycol
molecular weight
group
rhugh
Prior art date
Application number
PCT/CN2008/000674
Other languages
English (en)
French (fr)
Inventor
周卫东
廖小金
孙黎
张林忠
卢清松
沈世烨
杨丽姗
张德芳
林辉煌
张平
Original Assignee
厦门伯赛基因转录技术有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 厦门伯赛基因转录技术有限公司 filed Critical 厦门伯赛基因转录技术有限公司
Priority to EP08733888.5A priority Critical patent/EP2272875B1/en
Priority to US12/936,164 priority patent/US9840546B2/en
Priority to JP2011502208A priority patent/JP5458416B2/ja
Priority to MX2010010953A priority patent/MX2010010953A/es
Priority to CN200880009718XA priority patent/CN101809038B/zh
Priority to DK08733888.5T priority patent/DK2272875T3/da
Priority to PT87338885T priority patent/PT2272875E/pt
Priority to CA2720306A priority patent/CA2720306C/en
Priority to AU2008353850A priority patent/AU2008353850B2/en
Priority to RU2010136327/10A priority patent/RU2488598C2/ru
Priority to KR1020107022013A priority patent/KR101521674B1/ko
Priority to PCT/CN2008/000674 priority patent/WO2009121210A1/zh
Priority to PL08733888T priority patent/PL2272875T3/pl
Priority to ES08733888.5T priority patent/ES2453946T3/es
Priority to BRPI0822530-3A priority patent/BRPI0822530B1/pt
Publication of WO2009121210A1 publication Critical patent/WO2009121210A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention belongs to the technical field of biological preparations. Specifically, it relates to a highly biologically active double-stranded polyethylene glycol modified growth hormone, a preparation method thereof, and the use of the obtained pegylated growth hormone in the pharmaceutical field. Background technique
  • Human growth hormone is a protein hormone secreted by the anterior pituitary gland.
  • the precursor consists of 217 amino acid residues.
  • the first 26 amino acid residues constitute the signal peptide, and the other 191 amino acid residues constitute the mature molecule. It has 2 pairs of intramolecular disulfide bonds (Cys79 and Cysl91, Cys208 and Cys215), aglycosylation, molecular weight 22kD, and the sequence is shown as SEQ ID NO: 1 (NCBI: P01241, AAA72260; Denoto FM, et al. Human growth Nucleic acid sequence and mRNA structure: possible alternative splicing.
  • Recombinant human growth hormone therapy in malnourished dialysis patients a randomized controlled study. Am. J. Kidney Dis. , 32(3): 454-463, 1998; Neely EK, Use and abuse of human growth hormone. Annu. Rev. Med., 45: 407-410, 1994).
  • Recombinant human growth hormone (rHuGH) produced by recombinant DNA technology has proven its clinical efficacy and safety after more than 20 years of clinical application.
  • rHuGH is useful in the treatment of short stature, burns, trauma, fractures, hemorrhagic ulcers, renal failure, AIDS, anabolic disorders, endogenous auxin deficiency shortness, Turner syndrome, and adult growth hormone deficiency. It has obvious curative effect and has obvious effects on anti-aging treatment; rHuGH is currently the only effective drug for treating short stature. As of 2001 In March, the US FDA approved the indications for rHuGH to enter clinical studies: intensive treatment of nitrogen retention for severe burns, short bowel syndrome (independent or combined with glutamine), and AIDS-related growth arrest.
  • rHuGH adolescent endogenous auxin deficiency short stature
  • Turner syndrome-related short stature adolescent spontaneous or organ auxin deficiency short stature
  • Prader-Willi syndrome Premature growth disorders
  • AIDS-related catabolic disorders growth retardation associated with chronic renal failure
  • adult auxin deficiency adolescent endogenous auxin deficiency short stature
  • Polyethylene glycol is an inert, non-toxic, biodegradable organic polymer that has important applications in biotechnology and pharmaceuticals.
  • the PEG modification technique is the attachment of PEG to the active protein by covalent attachment.
  • PEGylation of protein drugs their traits are significantly improved, including prolonged drug half-life, decreased immunogenicity, improved safety, enhanced efficacy, reduced frequency of administration, improved drug solubility and water solubility, and resistance to protease digestion. Enhanced, convenient controlled release of drugs, etc. (Inada et al. J. Bioact. and Compatible Polymers, 5, 343, 1990; Delgado, et al.
  • U.S. Patent No. 4,179,337 discloses that the binding of PEG to proteins such as enzymes and insulin reduces the immunogenicity of the protein while significantly reducing the cytological activity of the protein, while still retaining a certain proportion of the activity of the original protein. This effect is in G-CSF (Satake-Ishikawa, et al. Cell Structure and Function, 17, 157-160, 1992), IL-2 (Katre, et al. Proc. Natl. Acad. Sci.
  • TNF- ⁇ TNF- ⁇
  • EL-6 Inoue, et al. J ⁇ ab. Clin. Med., 124, 529, 1994 ) and found in CD4-IgG (Chamow, et al. Bioconj. Chem., 5, 133, 1994).
  • U.S. Patent No. 5,824,784 utilizes a PEG-modified aldehyde-terminated agent to achieve a single-modified PEG-G-CSF at a fixed site (protein N-terminal amino acid).
  • the PEG-NHS modifier synthesized by the N-hydroxysuccinimide activation method forms an amide bond with the ⁇ -amino group of the lysine of G-CSF.
  • PEG-NHS has high chemical activity and poor selectivity, and it is difficult to obtain a modified product with a single site modification at a fixed site.
  • the single modified product is more uniform than the multi-modified product, which is advantageous for separation and purification, easy for quality control during large-scale preparation, and guarantees batch-to-batch stability.
  • PEGylated therapeutic protein drugs have been used in the clinic. Such as PEGylated adenosine deaminase (Adagen.RTM, Enzon Pharmaceuticals); PEGylated L-asparaginase (Oncapspar.RTM, Enzon Pharmaceuticals); PEGylated interferon alb (PEG-Intron.RTM, Schering-Plough) and pegylated interferon a2a (Pegasys, Roche); PEGylated granulocyte colony-stimulating factor (Neulasta.RTM, Amgen ) PEG moiety (or PEG) 0 medicament quite clear in vivo metabolic processes, one kind has proven good which is safe, no side effects of the drug modifier.
  • PEGylated adenosine deaminase Adagen.RTM, Enzon Pharmaceuticals
  • PEGylated L-asparaginase Oncapspar.RTM, Enzon Pharmaceuticals
  • PEG capable of binding to a protein drug usually needs to be derivatized so that one or both terminal groups at both ends of the PEG are chemically activated to have an appropriate functional group, and the functional group is active against at least one of the drugs to be bound, and can form with it.
  • a stable covalent bond For example, PEG can be attached to ⁇ - ⁇ 2 of the Lys residue in the protein peptide chain, or to ⁇ - ⁇ 2 of the amino acid residue of the protein peptide chain.
  • Polyethylene glycols that have been used to modify proteins typically come in three forms: linear molecular form ( ⁇ 0593868; Yu-Sen Wang et al. Advanced Drug Delivery Reviews, 54: 547-570, 2002; Yu-Sen Wang et al.
  • Li Weihua et al. (Chinese Patent Publication No.: CN 1477126A) describes a process for preparing PEG-modified growth hormone.
  • the method preferably performs a bifurcation PEG (mPEGn-NHS) modification reaction of growth hormone at a pH of 6.5-7.0, and the purified growth hormone bifurcated PEG unit dot modification is assayed for biological activity by a rat pituitary rat method.
  • the results showed that an equal amount of polyethylene glycol growth hormone conjugate (PEG is double-stranded PEG-NHS, molecular weight 40kD) with daily growth of growth
  • PEG polyethylene glycol growth hormone conjugate
  • molecular weight 40kD molecular weight 40kD
  • the invention provides a method for preparing double-stranded pegylated growth hormone, comprising the steps of:
  • Y-branched double-stranded polyethylene glycol is contacted with a growth hormone, preferably human growth hormone, preferably the molar ratio of the growth hormone to the double-stranded polyethylene glycol is about 1:2;
  • step b) detecting the polyethylene glycol unit dot modified product obtained in the step a) in an appropriate concentration of SDS-PAGE, preferably 12% SDS-PAGE, wherein the product is two bands or a band having a small apparent molecular weight the Lord;
  • a purification step is also included, preferably purified using a gel chromatography method such as Q Sepharose FF chromatography, DEAE Sepharose FF chromatography or MacroCap SP chromatography.
  • a gel chromatography method such as Q Sepharose FF chromatography, DEAE Sepharose FF chromatography or MacroCap SP chromatography.
  • the present invention provides a method for producing a double-stranded pegylated growth hormone, wherein the double-stranded polyethylene glycol is a Y-type polyethylene glycol having the following structural formula (I),
  • P ⁇ n P b is the same or different polyethylene glycol; j is an integer from 1 to 12; R ⁇ H, 12 substituted or unsubstituted fluorenyl, substituted aryl, aryl fluorenyl or hydrazine And: 3 ⁇ 4 are each independently a linking group, wherein ⁇ , 3 ⁇ 4(( ⁇ 2 ) ⁇ , ⁇ 2 is a group selected from the group consisting of: (CH 2 )n, (CH 2 ) n OCO, (CH 2 ) n NHCO, (CH 2 ) n CO, and n is an integer from 1 to 10; F is a terminal group selected from the group consisting of hydroxyl, carboxyl, ester, acid chloride, hydrazide, maleoyl
  • the imine, pyridine disulfide can react with the therapeutic drug or the amino, hydroxyl or thiol group on the substrate to form a covalent bond.
  • the present invention provides
  • R and R' are unrelated low molecular weight sulfhydryl groups, preferably -C4 alkyl groups, most preferably methyl groups; m and m' characterize the degree of polymerization, any integer; m+m' is preferably from 600 to 1500; j is from 1 to 12 An integer of H, d- 12 substituted or unsubstituted fluorenyl, substituted aryl, arylalkyl or heterofluorenyl; F is an end group selected from the group consisting of: ⁇ 'hydroxyl, carboxyl, ester The group, the acid chloride, the hydrazide, the maleimide, the pyridine disulfide, can react with the therapeutic drug or the amino, hydroxyl or thiol group on the substrate to form a covalent bond.
  • the present invention provides a process for the preparation of a double-stranded pegylated growth hormone, wherein the Y-type polyethylene glycol has the following structural formula (III):
  • R and R' are unrelated low molecular weight alkyl groups, preferably C r C 4 fluorenyl groups, most preferably methyl groups; m and m' characterize the degree of polymerization, any integer; m+m' is preferably from 600 to 1500, most preferably 910
  • the polyethylene glycol has a total average molecular weight of from about 26 kD to 60 kD, preferably 40 kD ; j is an integer from 1 to 12.
  • the present invention provides a method for producing a double-stranded pegylated growth hormone, wherein the double-stranded polyethylene glycol is a U-type polyethylene glycol having the following structural formula (IV),
  • R and R are independently independent low molecular weight alkyl groups, preferably -C 4 fluorenyl; n and n, characterizing the degree of polymerization, being any integer; n+n' is between 600 and 1500, most preferably 910;
  • the U-type polyethylene glycol has an average molecular weight of from about 26 kD to 66 kD, and most preferably about 40 kD.
  • the invention provides a method of making a double-stranded pegylated growth hormone comprising the steps of:
  • polyethylene glycol represented by the following formula (III) a) contacting polyethylene glycol represented by the following formula (III) with human growth hormone in a solution of pH 9.0 or 10.5, wherein the molar ratio of the human growth hormone to the double-stranded polyethylene glycol is about 1:2. ;
  • R and R' are unrelated low molecular weight sulfhydryl groups, preferably d-fluorenyl, most preferably methyl; m+m' is 910; j is an integer from 1 to 12; and the total average molecular weight of polyethylene glycol is about 40 kD ;
  • step b) detecting the polyethylene glycol unit dot modification product obtained in step a) in 12% SDS-PAGE, wherein the product is two bands;
  • the gel chromatography method is selected from Q Sepharose FF chromatography, DEAE Sepharose FF chromatography or MacroCap SP chromatography.
  • the present invention also provides a pegylated growth hormone prepared by the above method, wherein the growth hormone is a recombinant growth hormone extracted from a natural source or obtained by recombinant biotechnology, preferably having the sequence of SEQ ID NO: 1.
  • the present invention provides a polyethylene glycol prepared by the above process.
  • Growth hormone wherein the PEGylated growth hormone molecule: 62 kD, is represented by the following formula (VII):
  • R and R' are unrelated low molecular weight sulfhydryl groups, preferably C r C 4 fluorenyl groups, most preferably methyl groups; m+m' is 910; j is an integer from 1-12.
  • the invention also provides a method of preparing a PEGylated growth hormone preparation comprising the steps of:
  • U- or Y-branched double-stranded polyethylene glycol and growth hormone in a solution having a pH of not less than 8.0, preferably not less than 9.0, preferably not less than 9.5, preferably not less than 10.0, most preferably 10.5
  • the human growth hormone is contacted, preferably the molar ratio of the growth hormone to the double-stranded polyethylene glycol is about 1:2;
  • step b) detecting the polyethylene glycol unit dot modified product obtained by the step a) in a suitable concentration of SDS-PAGE, preferably 12% SDS-PAGE, wherein the product is two bands;
  • the recovered product is a mixture mainly composed of a polyethylene glycol unit dot modified product having a low apparent molecular weight, wherein the SDS-PAGE content of the polyethylene glycol unit dot modified product having a low apparent molecular weight is not less than 70%.
  • a purification step is also included, preferably purified using a gel chromatography method such as Q Sepharose FF chromatography, DEAE Sepharose FF chromatography or MacroCap SP chromatography.
  • a gel chromatography method such as Q Sepharose FF chromatography, DEAE Sepharose FF chromatography or MacroCap SP chromatography.
  • the present invention also provides a method of preparing a pegylated growth hormone preparation, wherein the double-stranded polyethylene glycol is a Y-type polyethylene glycol having the following structural formula (I),
  • PP b is the same or different polyethylene glycol; j is an integer from 1 to 12; R ⁇ H, C M2 substituted or unsubstituted alkyl, substituted aryl, aryl fluorenyl or heterofluorenyl; ⁇ 2 are each independently a linking group, wherein 1 is (03 ⁇ 4)tician, ⁇ 2 is a group selected from the group consisting of: (CH 2 )n, (CH 2 ) n OCO, (CH 2 ) n NHCO, (CH 2 ) n CO, and n is an integer from 1 to 10; F is a terminal group selected from the group consisting of hydroxyl, carboxyl, ester, acid chloride, hydrazide, maleimide, pyridine
  • the disulfide can form a covalent bond with the therapeutic drug or the amino, hydroxyl or thiol group on the substrate.
  • the present invention also provides a process for preparing a pegylated growth hormone preparation, wherein the Y-type polyethylene glycol has the following structural formula ( ⁇ ):
  • R and R' are unrelated low molecular weight sulfhydryl groups, preferably dC 4 alkyl groups, most preferably methyl groups; m and m' characterize the degree of polymerization, any integer; m+m' is preferably from 600 to 1500, most preferably 910; Is an integer from 1 to 12; ⁇ is 11, CL 12 substituted or unsubstituted alkyl, substituted aryl, arylalkyl or heteroalkyl; F is a terminal group selected from the group consisting of: hydroxy, carboxy , an ester group, an acid chloride, a hydrazide, a maleimide, a pyridine disulfide, which can form a covalent bond with a therapeutic drug or an amino group, a hydroxyl group or a thiol group on the substrate.
  • the present invention also provides a process for preparing a pegylated growth hormone preparation, wherein the Y-type polyethylene glycol has the following structural formula ( ⁇ ):
  • R and R' are unrelated low molecular weight sulfhydryl groups, preferably C r C 4 alkyl groups, most preferably methyl groups;
  • m' characterize the degree of polymerization as any integer; m+m' is preferably 600 to 1500, most preferably 910; j is an integer from 1 to 12; preferably the total average molecular weight of the polyethylene glycol is from about 26 kD to 60 kD, preferably It is 40 kD.
  • the present invention also provides a method of preparing a pegylated growth hormone preparation, wherein the double-stranded polyethylene glycol is a U-type polyethylene glycol having the following structural formula (IV),
  • R and R are independently independent low molecular weight alkyl groups, preferably CrC 4 fluorenyl; 1 and 11, characterizing the degree of polymerization, is any integer; n+n' is between 600 and 1500, most preferably 910; the U-type polyethylene glycol has an average molecular weight of from about 26 kD to 66 kD, most preferably about 40. kD.
  • the invention also provides a method of preparing a pegylated growth hormone preparation comprising the steps of:
  • polyethylene glycol represented by the following formula (III) is contacted with human growth hormone in a solution of pH 9.0 or 10.5, wherein the molar ratio of the human growth hormone to the double-stranded polyethylene glycol is about 1: 2;
  • R and R' are independently independent low molecular weight sulfhydryl groups, preferably dC 4 alkyl groups; m+m' is 910, j is an integer from 1 to 12; and the total average molecular weight of polyethylene glycol is about 40 kD;
  • the gel chromatography method is selected from the group consisting of Q Sepharose FF chromatography, DEAE Sepharose FF chromatography or MacroCap SP chromatography, and the SDS-PAGE content of the polyethylene glycol unit dot modified product having a low apparent molecular weight in the recovered product is not It is less than 70%, preferably not less than 80%, and most preferably not less than 90%.
  • the present invention also provides a PEGylated growth hormone preparation prepared by the above method, wherein the growth hormone is a recombinant growth hormone extracted from a natural source or obtained by recombinant biotechnology, preferably having the SEQ ID NO: 1 sequence.
  • the polyethylene glycol unit dot modified product in the PEGylated growth hormone preparation is as shown in the following formula (VII):
  • R and R' are unrelated low molecular weight sulfhydryl groups, preferably C r C 4 fluorenyl groups, most preferably methyl groups; m+m' is 910; j is an integer from 1 to 12, and the PEGylated growth hormone is prepared
  • the SDS-PAGE content of the polyethylene glycol unit dot modified product having a low apparent molecular weight is not less than 70%, preferably not less than 80%, and most preferably not less than 90%.
  • the recombinant human growth hormone is artificially synthesized or expressed by an expression system selected from the group consisting of: a prokaryotic system such as Escherichia coli; a eukaryotic yeast system such as Pichia; an insect cell system ; and mammalian cell systems such as CHO cells.
  • the invention also provides a composition
  • a composition comprising a pharmaceutically effective amount of the above-described pegylated growth hormone or pegylated growth hormone preparation and a pharmaceutically acceptable carrier or excipient, preferably comprising mannitol, Amino acids, sodium chloride, acetic acid and sodium acetate, wherein the amino acids are preferably aspartic acid, asparagine, lysine and glycine.
  • the present invention also provides the use of the above-described PEGylated growth hormone or pegylated growth hormone preparation or composition for the preparation of a medicament for treating a disease requiring treatment with growth hormone and anti-aging treatment, which requires
  • the disease treated with growth hormone is preferably selected from the group consisting of short stature, burns, wounds, fractures, hemorrhagic ulcers, renal failure, AIDS, endogenous auxin deficiency short stature, Turner syndrome, anabolic disorders, and adult growth hormone deficiency.
  • the invention also provides a method of treating a patient suffering from a disease requiring treatment with growth hormone and an anti-aging treatment, the method comprising administering to the patient a therapeutically effective amount of the above polyethylation A glycolated growth hormone or pegylated growth hormone preparation or composition, wherein the disease requiring treatment with growth hormone is preferably selected from the group consisting of short stature, burns, wounds, fractures, hemorrhagic ulcers, renal failure, AIDS, endogenous Sexual auxin deficiency short stature, Turner syndrome, anabolic disorders, and adult growth hormone deficiency.
  • the disease requiring treatment with growth hormone is preferably selected from the group consisting of short stature, burns, wounds, fractures, hemorrhagic ulcers, renal failure, AIDS, endogenous Sexual auxin deficiency short stature, Turner syndrome, anabolic disorders, and adult growth hormone deficiency.
  • the present invention provides a highly biologically active double-stranded PEG-modified growth hormone and a process for the preparation thereof.
  • a significant feature of the present invention is that the amount of low cytological active ingredient in the PEG unit dot modification of growth hormone can be significantly reduced after optimizing the reaction conditions and separation methods.
  • the double-stranded PEG has a molecular weight of 40 kD
  • the low cytological activity unit spot modification is characterized by the complete separation of high cytologically active unit point modifications into 2 strips on a 12% SDS-PAGE separation gel. The apparent molecular weight of the band, and the low cytological activity unit point modifier is greater than the high cytological activity unit point modifier.
  • the rat model of the pituitary gland was used as the animal model, and the recombinant human growth hormone was used as the positive control.
  • the final preparation of the high cytological activity unit point modification was determined according to the Chinese Pharmacopoeia 2005 edition two appendix ⁇ P growth hormone bioassay. Biological activity. The biospecific activity of high cytological activity single point modification was significantly higher than that of common growth hormone, which was 1.5 times higher than that of common growth hormone.
  • the pharmacokinetic study of cynomolgus monkey showed that the average serum half-life was higher than that of common growth hormone. It has been extended by more than 20 times and has a long-lasting effect.
  • the double-stranded PEG-NHS modification reaction of growth hormone is carried out under the conditions of pH 8.0, and the reaction product is detected by SDS-PAGE electrophoresis, and silver staining is developed.
  • the PEG-spot modification product of growth hormone is two major bands, unlike previous reports (Ross Clark, Kenneth 01son, et al. Long-acting growth hormones produced by conjugation with polyethylene glycol. J. Biol Chem., 271: 21969-21977, 1996. Li Weihua, Dong Jian, et al., Long-acting growth hormone and pharmaceutical composition, Chinese Patent Publication No.: CN1477126A).
  • the double-stranded PEG-NHS modification of growth hormone in the range of ⁇ .0-10.5 was investigated.
  • the SDS-PAGE showed that the single-point modification product was 2 main bands, and the pH of the reaction increased with the reaction.
  • the content of the band with a small apparent molecular weight increased correspondingly to pH 10.0, and the modified product per unit point was mainly dominated by a band having a small apparent molecular weight.
  • the PEG unit dot modification of recombinant human growth hormone under the conditions of ⁇ .5 and pH 6.0 is separately prepared by a suitable gel chromatography purification process.
  • the pure PEG unit dot modification of recombinant human growth hormone at pH 6.0 is a distinct double band; the pure PEG unit dot modification of recombinant human growth hormone under the condition of ⁇ .5 is a band with a small apparent molecular weight.
  • the SDS-PAGE content is not less than 80%; only trace amount of substrate protein (not more than 0.5%) is detected.
  • the MALDI-TOF MS test confirmed that the modified products under the two pH conditions were all PEG unit point modifiers of growth hormone; the cytological activity test showed that the cytological activity of the single point modification under the condition of ⁇ .5 was significantly higher than that of pH6.
  • the single-site modification under the condition of .0 has a cytological specific activity about twice that of the latter.
  • the PEG modified product of the recombinant human growth hormone in the pH 6.0 condition is purified by Q Sepharose FF chromatography and MacroCap SP chromatography to prepare a product with a large apparent molecular weight.
  • Product The MALDI-TOF MS assay confirmed that the recombinant human growth hormone PEG modification was a PEG unit dot modification; the cytological activity assay showed that the cytokine specific activity was significantly lower than that of the recombinant human growth hormone PEG unit dot modifier under the condition of ⁇ .5. (apparent molecular weight is small) pure, the latter's cytological specific activity is about 3 times that of the former.
  • recombinant human growth hormone is used as a positive control, and the pituitary rat method is used to detect recombinant human growth under the condition of ⁇ .5.
  • the pituitary rat method is used to detect recombinant human growth under the condition of ⁇ .5.
  • In vivo biological activity of the PEG-NHS 40kD single point modification of hormones The recombinant human growth hormone was administered once a day for 6 consecutive administrations; the recombinant human growth hormone PEG unit dot modification was administered once in a dose consistent with the sum of the six doses of recombinant human growth hormone.
  • the biological activity of the recombinant human growth hormone PEG unit dot modification is significantly higher than that of the recombinant human growth hormone, which is more than 1.5 times the biological specific activity of the latter, and its pharmacology has long-term characteristics.
  • the pharmacokinetic study of cynomolgus monkeys showed that the recombinant human growth hormone PEG unit dot modification had a half-life longer than that of the conventional recombinant human growth hormone.
  • the present invention uses branched (U-branched and Y-branched) PEG derivatives to modify growth hormone.
  • the Y-branched PEG derivative used in the present invention is a novel branched PEG derivative, the structure of which is different from the linear PEG and the U-branched PEG, and the main difference from the U-branched PEG is: the invention adopts The two PEG branching chains of the Y-type PEG derivative are linked together by the N atom, and the two PEG branching chains of the U-type PEG derivative are linked together by the C atom.
  • the Y-type and U-type PEG modifications described in the present invention mainly occur in the protein or peptide N
  • the molecular composition of the quinoid PEG derivative is shown in the following formula (1):
  • PHP b is the same or different polyethylene glycol; j is an integer from 1 to 12; Ri is H, C 1-12 substituted or unsubstituted fluorenyl, substituted aryl, aryl fluorenyl or hydrazine ⁇ ⁇ 2 are each independently a linking group, wherein X is (CH 2 ) n , and X 2 is a group selected from the group consisting of: (CH 2 ) n , (CH 2 ) n OCO , (CH 2 ) n HCO, (CH 2 ) n CO, and n is an integer from 1 to 10; F is a terminal group selected from the group consisting of a hydroxyl group, a carboxyl group, an ester group, an acid chloride, a hydrazide, and a male
  • the imide, pyridine disulfide can form a covalent bond with a therapeutic drug or an amino group, a hydroxyl group or a thiol group on the
  • the Y-shaped PEG derivative is in the formula & ? 1) It may be the same or different polyethylene glycol, as shown in the following formula ( ⁇ ):
  • R and R are independently unrelated low molecular weight alkyl groups, preferably -C4 fluorenyl, most preferably methyl; m and m, characterizing degree of polymerization, being any integer; m+m' is preferably from 600 to 1500, most preferably 910; 11. d. 12 substituted or unsubstituted alkyl, substituted aryl, aralkyl, or heteroalkyl; j is an integer from 1-12.
  • F is a terminal group selected from the group consisting of a hydroxyl group, a carboxyl group, an ester group, an acid chloride, a hydrazide, a maleimide, a pyridine disulfide, which can be formed by reacting with a therapeutic drug or an amino group, a hydroxyl group or a thiol group on a substrate. Covalent bond.
  • the polyethylene glycol has a total average molecular weight of from about 26 kD to 60 kD, and most preferably about 40 kD.
  • the invention provides a pegylated growth hormone having the structure of formula (VI):
  • R and R are unrelated low molecular weight alkyl groups, preferably C r C 4 fluorenyl groups, most preferably methyl groups;
  • j is an integer from 1 to 12;
  • m and m characterizing degree of polymerization, being any integer;
  • m+m preferably from 600 to 1500;
  • ⁇ is 11, C 12 substituted or unsubstituted alkyl, substituted aryl, aralkyl, or heteroalkyl;
  • F is a terminal group selected from the group consisting of: hydroxy, carboxy , an ester group, an acid chloride, a hydrazide, a maleimide, a pyridine disulfide, which can form a covalent bond with a therapeutic drug or an amino group, a hydroxyl group or a thiol group on the substrate.
  • a Y-type PEG derivative molecule has the formula: (III):
  • R and R are unrelated low molecular weight sulfhydryl groups, preferably C r C 4 alkyl groups, most preferably methyl groups; j is
  • U-type PEG derivative molecule (UPEG-NHS) has the formula: (IV):
  • R and R are independently independent low molecular weight sulfhydryl groups, preferably fluorenyl groups; n and n' characterize the degree of polymerization, being any integer; n+n, between 600 and 1500, most preferably 910; PEG average The molecular weight is from about 26 kD to 66 kD, and most preferably about 40 kD.
  • the PEG moiety is covalently bound to the amino group (-NH 2 ) of the protein by a nucleophilic substitution reaction of an activated derivative such as polyethylene glycol succinimide ester (PEG-NHS) of YPEG and UPEG, including The a-amino group of the N-terminus of the protein and the ⁇ -amino group of the lysine residue.
  • PEG-NHS polyethylene glycol succinimide ester
  • the polyethylene glycol has a total average molecular weight of from about 26 kD to 60 kD, most preferably 40 kD.
  • the pegylated growth hormone according to the present invention has a formula (VII) port junction structure 1 J:
  • R and R' are unrelated low molecular weight sulfhydryl groups, preferably dC 4 fluorenyl groups, most preferably methyl groups; j is an integer from 1 to 12; m and m, characterizing the degree of polymerization, being any integer; m+m, preferably 600 To 1500.
  • the Y-branched PEG is bound to the growth hormone molecule by a unit point. m and m, which may be the same or different integers.
  • the molecular weight of YPEG-GH in the above formula mainly depends on the degree of polymerization m and mO m+m' is preferably 600 to 1500, and the average molecular weight of the corresponding YPEG is from about 26 kD to about 66 kD; wherein m+m' is preferably 795 to 1030, corresponding to YPEG
  • the average molecular weight is from about 35 kD to 45 kD; m+m' is particularly preferably from 885 to 1030, the corresponding average molecular weight of YPEG is from about 39 kD to lj 45 kD; m+m' is most preferably 910, and the average molecular weight of the corresponding YPEG is about 40 kD.
  • the ratio of m and m may range from 0.5 to 1.5, preferably from 0.8 to 1.2.
  • the growth hormone of the present invention may be a growth hormone extracted from a natural source or obtained by recombinant biotechnology.
  • the growth hormone is a human growth hormone having the sequence shown in SEQ ID NO: 1 extracted from a natural source or obtained by recombinant biotechnology.
  • the human growth hormone is recombinant human growth hormone.
  • the growth hormone may be synthetic or may be expressed by a prokaryotic system such as Escherichia coli (expressed by E. Coli or a eukaryotic yeast system such as Pichia pastoris, or other insect cell systems or mammalian cells). Systems such as those expressed by CHO. Methods for preparing natural or recombinant growth hormones and methods for detecting the activity of growth hormone and its PEG-modified products are prior art in the art.
  • the YPEG-GH and UPEG-GH of the present invention have the same clinical use as GH, and are suitable for treating short stature, burns, wounds, fractures, hemorrhagic ulcers, renal failure, AIDS, anabolic disorders, adult growth hormone deficiency, and the like. Anti-aging treatment.
  • the YPEG-GH and UPEG-GH of the present invention can be administered to a patient in the form of a composition comprising a pharmaceutically effective amount of YPEG-GH or UPEG-GH and a pharmaceutically acceptable carrier or excipient.
  • another aspect of the invention provides a composition comprising a pharmaceutically effective amount of a PEGylated growth hormone of the invention and a pharmaceutically acceptable carrier or excipient.
  • the pharmaceutically acceptable carriers employed in the present invention include pharmaceutically acceptable carriers, excipients, or stabilizers which are non-toxic to the cells or mammals to which they are administered at the dosages and concentrations employed.
  • a generally physiologically acceptable carrier is an aqueous pH buffer solution.
  • physiologically acceptable carriers include buffers such as phosphates, citrates, and other organic acids; antioxidants including ascorbic acid; low molecular weight (up to 10 residues) polypeptides; a protein such as protein, gelatin, or immunoglobulin; a hydrophilic polymer such as polyvinylpyrrolidone; an amino acid such as glycine, aspartic acid, glutamine, asparagine, arginine or lysine; Monosaccharides include glucose and other sugars such as mannose, disaccharide or dextrin; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or such as TWEEN, Polyethyl Nonionic surfactants such as diols, and PLURONICS.
  • buffers such as phosphates, citrates, and other organic acids
  • antioxidants including ascorbic acid
  • compositions are preferably sterile and generally free of undesirable materials. These compositions can be sterilized by conventional sterilization techniques.
  • the composition further comprises mannitol, an amino acid, sodium chloride, acetic acid and sodium acetate, wherein the amino acids are preferably lysine, aspartic acid, asparagine and glycine.
  • the present invention provides a PEGylated growth hormone of the present invention or a composition comprising the PEGylated growth hormone of the invention for the preparation of a medicament for treating a disease requiring treatment with growth hormone and an anti-aging treatment.
  • the disease requiring treatment with growth hormone is selected from the group consisting of short stature, burns, wounds, fractures, hemorrhagic ulcers, renal failure, AIDS, endogenous auxin deficiency shortness, Turner syndrome, anabolic disorders and Adult growth hormone deficiency and so on.
  • Figure 1 The result of non-reducing SDS-PAGE electrophoresis of the YPEG-NHS 40kD or UPEG-NHS 40kD modification reaction of rHuGH at pH 8.0, the concentration of the separation gel was 12%, and silver staining was developed.
  • Lane 1 marker, LMW, GE Healthcare ;
  • Lane 2 rHuGH of YPEG-NHS modification reaction sample, reaction pH 8.0, the sample volume 2 ⁇ ⁇ ;
  • Lane 3 rHuGH of YPEG-NHS modification reaction sample, reaction pH 8.0, Loading amount 5 g;
  • Lane 4 UHu-NHS modification reaction of rHuGH, reaction pH 8.0, loading amount 5 ⁇ ⁇ .
  • Figure 2 The results of non-reducing SDS-PAGE electrophoresis of the YPEG-NHS 40kD modification reaction of rHuGH under different ⁇ conditions, the separation gel concentration was 12%, and silver staining was developed.
  • Lane 1 YPEG-NHS modification reaction of rHuGH, reaction pH 6.0;
  • Lane 2 YPEG-NHS modification reaction of rHuGH, reaction pH 7.0;
  • Lane 3 YPEG-NHS modification reaction of rHuGH, reaction pH 8.0
  • Lane 4 YPEG-NHS modification reaction of rHuGH, reaction pH 9.0;
  • Lane 5 YPEG-NHS modification reaction of rHuGH, reaction pH 9.5;
  • Lane 6 YPEG-NHS modification reaction of rHuGH, reaction ⁇ . ⁇ ;
  • Lane 7 YPEG-NHS modification reaction of rHuGH, reaction pH 10.5;
  • Lane 8 marker, LMW, GE Healthcare.
  • the sample loading was 5 g for each sample.
  • Figure 3 UPEG-NHS modification reaction of non-reduced type of rHuGH under different pH conditions The results of SDS-PAGE electrophoresis showed that the separation gel concentration was 12%, and silver staining was developed.
  • Lane 1 rHuGH UPEG-NHS modification reaction, reaction pH 6.0; Lane 2: rHuGH UPEG-NHS modification reaction, reaction pH 7.0; Lane 3: rHuGH UPEG-NHS modification reaction, reaction pH 8.0
  • Lane 4 UPEG-NHS modification reaction of rHuGH, reaction pH 9.0; Lane 5: UPEG-NHS modification reaction of rHuGH, reaction pH 9.5; Lane 6: UPEG-NHS modification reaction of rHuGH, reaction ⁇ . ⁇ ; Lane 7: UPEG-NHS modification reaction of rHuGH, reaction pH 10.5; Lane 8: marker, LMW, GE Healthcare.
  • the sample loading for each sample was 5 ⁇ ⁇ .
  • Figure 4 Non-reducing SDS-PAGE electrophoresis of purely non-reducing SDS-PAGE of rHuGH YPEG-NHS 40kD or UPEG-NHS 40kD single-site modification under the conditions of ⁇ 6.0 and ⁇ 10.5, the separation gel concentration was 12%, and silver staining was developed.
  • Lane 1 UPEG-rHuGH U10.5, loading lO g
  • Lane 2 UPEG-rHuGH U10.5, loading 2 g
  • Lane 3 UPEG-rHuGH U6.0, loading lO g
  • Lane 4 UPEG-rHuGH U6.0, loading 2 g
  • Lane 5 marker, LMW, GE Healthcar
  • Lane 6 YPEG-rHuGH Y10.5, loading 10 g
  • Lane 7 YPEG-rHuGH Y10.5, Loading amount 2 g
  • Lane 8 YPEG-rHuGH Y6.0, loading amount l ( ⁇ g
  • Lane 9 YPEG-rHuGH Y6.0, loading amount 2 g
  • Lane 10 rHuGH, loading amount lOOng
  • Lane 11 rHuGH, loading 50 ng.
  • Figure 5 Results of cytological activity of pure UPEG-NHS 40kD single-point finish of rHuGH at pH6.0 and ⁇ 10.5, 2 parallel plates.
  • Figure 6 Results of cytological activity of pure YPEG-NHS 40kD single-site modification of rHuGH at pH 6.0 and pH 10.5, 2 parallel plates.
  • Figure 7 YPEG-NHS 40kD single-site modification pure product of rHuGH at pH6.0, pH 9.0, pH 10.5 and MALDI-TOF MS of UPEG-NHS 40kD single-site modification pure product.
  • a YPEG-rHuGH, Y6;
  • b YPEG-rHuGH, Y9;
  • c YPEG-rHuGH, Y10.5;
  • d YPEG-rHuGH, Y6-1;
  • e UPEG-rHuGH, U6 ;
  • f UPEG-rHuGH, U9;
  • g UPEG-rHuGH, U10.5;
  • h UPEG-rHuGH, U6-1;
  • i YPEG-NHS, 40kD;
  • j UPEG-NHS, 40kD ;
  • k Protein Calibrate Standard II , BRUKER; 1: rHuGH m: Protein Calibrate
  • Figure 8 PEG-NHS 40kD modification of PEG-NHS 40kD modified product of rHuGH with a large apparent molecular weight and PEG-NHS 40kD of rHuGH under the condition of ⁇ .5
  • the result of the non-reducing SDS-PAGE of the pure product of the site modification was 12%, and the color of the separation gel was 12%.
  • Lane 1 YPEG-rHuGH Y10.5, loading 2 g; Lane 2: YPEG-rHuGH Y6.0-1, loading 2 ⁇ ⁇ ; Lane 3: UPEG-rHuGH U10.5, loading 2 g; Lane 4: UPEG-rHuGH U6.0-l, loading 2 g; Lane 5: rHuGH, loading 50 ng; Lane 6: rHuGH, loading lOOng; Lane 7: marker, LMW, GE Healthcare; Lane 8 : YPEG-rHuGH Yl 0.5, loading amount l ( ⁇ g; lane 9: YPEG-rHuGH Y6.0-1, loading amount lO g; lane 10: UPEG-rHuGH U10.5, loading amount l ( ⁇ g Lane 11: UPEG-rHuGH U6.0-l, loading 10 g.
  • Figure 9 Pure PEG unit dot modification (Y6-l, U6-1) with large apparent molecular weight of PEG-NHS 40kD modified product of rHuGH at pH 6.0 and PEG-NHS 40kD of rHuGH with ⁇ 10.5 Pure product of single-point modification (Y10.5, U10.5) The apparent molecular weight test results of reduced SDS-PAGE.
  • Lane 1 YPEG-rHuGH Y6-l+YPEG-rHuGH Y10.5, each 25 ng; Lane 2: YPEG-rHuGH Y6-1, 50 ng ; Lane 3: YPEG-rHuGH Yl 0.5, 50 ng ; Lanes 4, 6: blank; Lane 5: marker, HMW, GE Healthcare; Lane 7: UPEG-rHuGH U6-l+UPEG-rHuGH U10.5, each 25 ng ; Lane 8: UPEG-rHuGH U6-1, 50 ng; Lane 9: UPEG-rHuGH Ul 0.5 , 50ng.
  • Figure 10 Comparison of mean serum drug concentration-time curves for ⁇ ⁇ 1 rHuGH and YPEG-rHuGH (Y10.5) in a single subcutaneous injection of cynomolgus monkeys. detailed description
  • the U-type and Y-branched PEG modifications of recombinant human growth hormone were taken as 200mg UPEG-NHS and YPEG-NHS (average molecular halo 40kD, equal arm; batch numbers are ZZ004P182, ZZ004P167 respectively) (Beijing Keykai Technology Co., Ltd.) , dissolved in 2ml 2mM HC1 (Guangdong Guanghua Chemical Co., Ltd.); 50mg of rHuGH (Xiamen Tebao Bioengineering Co., Ltd.) and 50mM boric acid / borax Buffer (pH 8.0) (China Pharmaceutical Group Shanghai Chemical Reagent Co., Ltd.) made the total reaction volume 10 ml.
  • the final concentration of rHuGH reaction is 5 mg/ml, and the molar ratio of rHuGH to PEG-NHS is about 1:2.
  • the temperature was bathed at ⁇ 10 ° C for 2 h, and glacial acetic acid (Xihua Chemical Plant, Shantou City) was added to terminate the reaction at pH ⁇ 4.0.
  • Sampling was performed by SDS-PAGE electrophoresis, and silver staining was developed.
  • the results of SDS-PAGE electrophoresis are shown in Fig. 1. It can be seen from the electrophoresis results of Figure 1.
  • the main band of the modified product under pH 8.0 is double band, and the SDS-PAGE electrophoresis behavior of UPEG-NHS and YPEG-NHS modified reaction samples is consistent.
  • U-type and Y-branched PEG modifications of recombinant human growth hormone under different pH conditions were respectively taken as 200mg UPEG-NHS and YPEG-NHS (average molecular weight 40kD, equal arm; batch numbers are ZZ004P182, ZZ004P167 respectively) (Beijing Keykai Technology Co., Ltd.)
  • One part each was dissolved in 2 ml of 2 mM HC1 (Guangdong Guanghua Chemical Co., Ltd.); 50 mg of rHuGH (Xiamen Tebao Bioengineering Co., Ltd.) and the corresponding buffer were added respectively to make a total reaction volume of 10 ml.
  • reaction pH 6.0, 7.0 and 8.0 using the corresponding pH value of 10 mM PBNa buffer (China Pharmaceutical Group Shanghai Chemical Reagent Company), reaction pH 9.0, 9.5, 10.0 and 10.5 using the corresponding pH value of 50 mM borax buffer (China Pharmaceutical Group Shanghai Chemical Reagent company).
  • the final concentration of rHuGH reaction is 5 mg/ml, and the molar ratio of rHuGH to PEG-NHS is about 1:2.
  • glacial acetic acid Xifu Chemical Plant, Shantou City
  • the samples were subjected to SDS-PAGE electrophoresis and silver stained for color development; the gel electrophoresis results were analyzed using a gel imaging system (Model: FR-200, Shanghai Furi Technology Co., Ltd.).
  • the results of SDS-PAGE electrophoresis are shown in Figure 2 and Figure 3.
  • the results of the gel imaging system are shown in Table 1. It can be seen from the electrophoresis results that the main bands of the modified products under the conditions of pH 6.0-9.5 are obvious double bands, and the main band content of the apparent molecular weight increases correspondingly with the increase of the reaction pH; ⁇ . ⁇ and 10.5 conditions
  • the modified product is mainly based on a band having a small apparent molecular weight.
  • the SDS-PAGE electrophoresis behavior of UPEG-NHS and YPEG-NHS modified reaction samples was consistent.
  • the content refers to the band 1 of the modified product of PEG unit point of rHuGH (large apparent molecular weight) and band 2 (small apparent molecular weight) The relative percentage between.
  • Example 3 The content refers to the band 1 of the modified product of PEG unit point of rHuGH (large apparent molecular weight) and band 2 (small apparent molecular weight) The relative percentage between.
  • the final concentration of rHuGH reaction is 5 mg/ml
  • the molar ratio of rHuGH to PEG-NHS is about 1:2
  • the reaction pH is 10.5, 9.0 and 6.0, respectively
  • the temperature is ⁇ 10 °C for 2 h under shaking conditions, adding ice.
  • Acetic acid (Xifu Chemical Plant, Shantou City) terminated the reaction at pH ⁇ 4.0. Sampling was performed by SDS-PAGE electrophoresis, and silver staining was developed.
  • the PEG modification reaction sample of rHuGH was diluted 3 times with ultrapure water, and the pH value of the diluted sample was adjusted to 9.0 with NaOH or HC1, respectively.
  • the chromatographic column (Shanghai Jinhua Chromatography Equipment Factory) has a specification of O18mmx400mm
  • Q Sepharose FF packing (GE Healthcare) has a packing size of ⁇ D18mmx240mm and a bed volume (CV) of 61ml.
  • Q Sepharose FF column was cleaned in place with 0.5M NaOH 5ml/minx30min, 3CV was eluted with ddH 2 0 5ml/min, 3CV was eluted with lM NaCl 5ml/min, 20mM borax/boric acid-17mM NaCl (pH 9.0, A solution) 5CV was eluted at 5 ml/min.
  • the PEG modification reaction of rHuGH was applied to the ultrapure water dilution sample at a flow rate of 3 ml/min, and the eluent detection wavelength was 280 nm (AKTA Basic 100, GE Healthcare).
  • the second peak sample is collected as the target.
  • the DEAE Sepharose FF column was washed in place with 0.5 M NaOH 5 ml/min x 30 min, 3 CV eluted with ddH 2 0 5 ml/min, 3 CV eluted with 1 M NaCl 5 ml/min, 20 mM borax/boric acid (pH 9.0, solution A) 5 ml/ Min elutes 3CV.
  • the target buffer system was ultrafiltered to 3 mM NaAc/HAc-7 mM NaCl-5 mM Lys (pH 5.0) with a 5K ultrafilter (Millipore, polyethersulfone), and mannitol was added to a final concentration of 45 mg/ml, 0.2.
  • the pH 6.0 modified reaction product was named Y6 or U6, wherein the band with a large apparent molecular weight was named Y6-1 or U6-1, and the band with a small apparent molecular weight was named Y6-2 or U6-2; pH 9.0
  • the modified reaction product was named Y9 or U9; the ⁇ .5 modified reaction product was named Y10.5 or U10.5.
  • the GH-dependent rat lymphoma cell line Nb2-l 1 was used to detect the cytological activity of each sample of PEG-rHuGH.
  • Nb2-l l cells were diluted to a final concentration of 5 x 10 4 cells/ml.
  • GH national standard (batch number: 35-20002, lmg/ml/branch, 3IU/branch; purchased from China National Institute for the Control of Pharmaceutical and Biological Products) Pre-diluted to 100ng/ml (0.0003IU/ml), PEG-rHuGH Pre-diluted to 0.0003 IU/ml according to the pre-experiment results; on the basis of pre-dilution, each sample was further diluted by a half-thr gradient and then tested.
  • the sample activity calculation formula is as follows:
  • 0 ⁇ is the dilution factor of the sample to be tested equivalent to the semi-effect amount of the standard product
  • c 2 is the half-effect dilution factor of the standard
  • 0 1 is the pre-dilution factor of the sample to be tested
  • D 2 is the standard pre-dilution factor
  • the results of cytological activity test are shown in Table 2 and Figure 5 and Figure 6. Two parallel samples were detected simultaneously for each sample.
  • the cytological specific activity of the modified product (Y6) is the YPEG-NHS pH6.0 of rHuGH.
  • the cytological specific activity of the ⁇ ⁇ modified product (Y9) is
  • the cytological specific activity of the ⁇ 10.5 modified product (Y10.5) was Zi ⁇ xli ⁇ IU/mg; the cytological specific activity of Y10.5 was about twice that of Y6.
  • the cytological specific activity of the UPEG-NHS pH6.0 modified product (U6) of rHuGH was 8.85xl (T 2 IU/mg, and the cytological specific activity of the modified product of pH 9.0 (U9) was l ⁇ Sxlt ⁇ IU/mg;
  • the cytological specific activity of the pH10.5 modified product (U10.5) was 1.82 ⁇ 10 ⁇ 1 IU/mg; the cytological specific activity of U10.5 was about twice that of U6.
  • the PEG unit The cytological activity of the point-modified product (2 main bands) was correspondingly increased.
  • GH national standard is the standard. Standard lot number: 35-20002, lmg/ml/piece, 3IU/piece, purchased from China National Institute for the Control of Pharmaceutical and Biological Products.
  • the molecular weight of each sample of PEG-rHuGH was determined by the German BRUKER Autoflex III TOF/TOF mass spectrometer and the MALDI-TOF MS method.
  • Matrix using sinapinic acid SA, C "ri 12 0 5, MW 224.22; Lot 2006 236870 002, BRUKER
  • protein molecular weight standards using Protein BRUKER Company Calibration Standard I (Part No.206355) and Protein Calibration Standard II (Part No.207234)
  • the analysis software is flexAnalysis Ver.3.0.54.0. The results are shown in Fig. 7.
  • the MS molecular weights of the YPEG-NHS pH6.0 modified product (Y6), the pH 9.0 modified product (Y9) and the ⁇ 10.5 modified product (Y10.5) of rHuGH are all within the range of 102012 Daltons 10%,
  • the theoretical molecular weight of the YPEG unit-site modified rHuGH was consistent (the molecular weight of YPEG-NHS was 40 kD ⁇ 10%), indicating that Y6, ⁇ 9 and Y10.5 are both YPEG unit dot modifiers of rHuGH.
  • the MS molecular weights of rHuGH UPEG-NHS pH6.0 modified product (U6), pH 9.0 modified product (U9) and pH10.5 modified product (U10.5) are all within the range of 62012 Dalton ⁇ 10%,
  • the theoretical molecular weight of UPEG unit-site modified rHuGH was consistent (the molecular weight of UPEG-NHS was 40kD ⁇ 10%), indicating that U6, U9 and U10.5 are UPEG unit point modifiers of rHuGH.
  • the final concentration of rHuGH reaction is 5 mg/ml, and the molar ratio of rHuGH to PEG-NHS is about 1:2, and the reaction pH is 6.0.
  • the temperature was bathed at ⁇ 10 ° C for 2 h, and glacial acetic acid (Xifu Chemical Plant, Shantou City) was added to terminate the reaction at pH ⁇ 4.0.
  • rHuGH PEG modification reaction ultra-pure water dilution sample was loaded at a flow rate of 6 ml / min, A solution 10 ml / min eluted to the first peak completely washed out; replaced with 20 mM borax / boric acid - lOOmM NaCl (pH 9.0, B solution), 10 ml/min eluted until the second peak was completely washed out; replaced with 20 mM borax/boric acid-200 mM NaCl (pH 9.0, liquid C), eluted to a third peak at 10 ml/min.
  • the eluent detection wavelength was 280 nm (AKTA Basic 100, GE Healthcare). 0
  • the second peak sample was collected as the target.
  • the desired buffer system was ultrafiltered to 5 mM NaAc/HAc (pH 4.5) using a 5K ultrafilter (Millipore, polyethersulfone).
  • the chromatographic column (Shanghai Jinhua Chromatography Equipment Factory) has a specification of 0>12mmx300mm
  • MacroCap SP column was washed in place with 0.5M NaOH 1 ml/minx 3 Omin, 3CV at ddH 2 0 lml/min, 1M NaCl 1ml/minx3CV regeneration, 5mM NaAc/HAc (pH 4.5, A solution) lml/min Elute 5 CV.
  • Eluent detection wavelength 280nm (AKTA Basic 100, GE Healthcare collects 30% _45% B gradient elution 5th to 8th CV elution sample is the purpose of the sample.
  • 5K ultrafilter Micropore, polyether Sulfone
  • Ultrafiltration of the desired buffer system was replaced with 3 mM NaAc/HAc-7 mM NaCl-5 mM Lys (pH 5.0), mannitol was added to a final concentration of 45 mg/ml, and 0.2 ⁇ m was filtered to remove bacteria; SDS-PAGE was sampled.
  • Electrophoresis silver staining; residual sample - frozen at 70 ° C, sample number: U6-l, Y6-l.
  • SDS-PAGE electrophoresis results are shown in Figure 8, SDS-PAGE electrophoresis apparent molecular weight test results shown in the figure 9.
  • PEG-rHuGH sample was loaded onto each case 10 ⁇ ⁇ where small amounts were detected in a multi-site modification, each The sample substrate protein (rfiuGH) content did not exceed 0.5% (Fig. 8), and the main band content was not less than 80%.
  • the apparent molecular weight of SDS-PAGE electrophoresis of each sample of PEG-rHuGH was 1 main band, and the apparent molecular weight of Y6-1 was significantly larger than Y10.5.
  • the apparent molecular weight of U6-1 was significantly larger than U10.5 (Fig. 9). .
  • the molecular weight of each sample of PEG-rHuGH was determined by the German BRUKER autoflex TOF/TOF mass spectrometer and the MALDI-TOF MS method.
  • the detection method is the same as in the third embodiment. The results are shown in the figure
  • the MS molecular weights of Y6-1 and U6-1 are all within the range of 62012 Dalton ⁇ 10%, which is consistent with the theoretical molecular weight of PEG unit point modified rHuGH (the molecular weight of YPEG-NHS and UPEG-NHS is 40kD ⁇ 10%). All are PEG unit point modifiers.
  • the average cytological activity of Y10.5 was Z.OSxlO ⁇ IU/mg, and the average cytological activity of Y6-1 was 5.50xl (T 2 IU/mg; the average cytological activity of U10.5 was S xlO ⁇ The average cytological activity of IU/mg, U6-1 was 5.00xlO 2 IU/mg.
  • the average cytological activity of Y10.5 U10.5 was significantly higher than that of Y6 ⁇ l/U6-1, which was up to 3 Times around.
  • Rats with pituitary pituitary were used as animal models to determine the growth of YPEG-rHuGH (Y10.5) and UPEG-rHuGH (U10.5) in vivo in accordance with the Chinese Pharmacopoeia 2005 edition appendix ⁇ P growth hormone bioassay. Learning activity, that is, the effect of one week after one-time administration on the growth and development of the pituitary rat (without endogenous growth hormone) was observed.
  • Wistar rats SPF grade, male, born 26-28d, weight 60-80g; provided by the Experimental Animal Center of China National Institute for the Control of Pharmaceutical and Biological Products, animal certificate number: SCXK (Beijing) 2005-0004.
  • Rat pituitary gland was surgically removed under sterile conditions 2-3 weeks before the test, and it was normally reared in a secondary laboratory to restore it.
  • Screened qualified pituitary rats divided into 10 groups according to body weight, each group of 10, specifically: negative control (blank solvent) group; positive control rHuGH (GH national standard, prepared by China National Institute for the Control of Pharmaceutical and Biological Products, specifications 3Il mg low (2.7111-kg- 1 ), medium (SJIU-kg 1 ), high (10.
  • Y10.5 and U10.5 were prepared at an estimated titer of 3 IU/mg. The drug was administered in a volume of 0.5 ml; the negative control group was given only the solvent, once a day, and continuously for 6 times.
  • the rats were sacrificed 24 hours after the last administration of the positive control group, and the body weight and the width of the humerus epiphyseal plate were measured.
  • the data were processed according to the Chinese Pharmacopoeia 2005 edition appendix ⁇ P growth hormone bioassay and Appendix XIV biometric statistical method.
  • YPEG-rHuGH The bioavailability of YPEG-rHuGH (Y10.5) is 5.0 IU'mg, and the bioavailability of UPEG-rHuGH (U10.5) is S ⁇ IU.mg- 1 , which is more than 1.5 times that of ordinary rHuGH.
  • YPEG-rHuGH (Y10.5) and UPEG-rHuGH (U10.5) have higher biological activity and long-acting pharmacological effects for promoting the growth of animal organisms than one dose of rHuGH administered daily.
  • YPEG-rHuGH (Y10.5) The cytotoxic half-life of cynomolgus monkeys was tested with 6 cynomolgus monkeys, 3 males and 3 females, weighing 3.24-5.48 kg (Guangxi Beihai Yuqi Experimental Animal Science and Technology Co., Ltd., certificate number: SCXK) (Gui) 2005-0005).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Diabetes (AREA)

Description

双赚乙二醇鶴的生长激素及其制备旅和应用 技术领域
本发明属生物制剂技术领域。 具体涉及高生物活性的双链聚乙二醇 修饰生长激素及其制备方法， 以及获得的聚乙二醇化生长激素在制药领 域中的应用。 背景技术
人生长激素（HUGH)是人脑垂体前叶分泌的一种蛋白质激素， 前体 由 217个氨基酸残基组成，其中前 26个氨基酸残基组成信号肽，其它 191 个氨基酸残基组成成熟分子； 具有 2对分子内二硫键（Cys79和 Cysl91， Cys208和 Cys215 )， 无糖基化， 分子量 22kD， 序列如 SEQ ID NO: 1所 示 (NCBI ： P01241,AAA72260; Denoto F M, et al. Human growth hormone DNA sequence and mRNA structure: possible alternative splicing. Nucleic Acids Res., 9: 3719-3730, 1981; Roskam W, et al. Molecular cloning and nucleotide sequence of the human growth hormone structural gene. Nucleic Acids Res., 7: 305-320, 1979; Martial J A， et al. Human growth hormone ： Complementary DNA cloning and expression in bacteria. Science, 205: 602-607, 1979; Chen E Y，et al.The human growth hormone locus: nucleiotide sequence, biology and evolution. Genomics, 4: 479-497, 1989)。 其主要功能 为促进细胞、器官和骨骼的生长，并与机体的合成代谢密切相关（Iglesias P, et al. Recombinant human growth hormone therapy in malnourished dialysis patients: a randomized controlled study. Am. J. Kidney Dis.,32(3): 454-463,1998； Neely E K， Use and abuse of human growth hormone. Annu.Rev.Med.，45:407-410, 1994)。利用重组 DNA技术生产的重组人生长 激素 （rHuGH) 经过二十多年的临床应用， 已证明其在临床上的有效性 和安全性。
大量的研究结果表明， rHuGH对治疗矮小症、 烧伤、 创伤、 骨折、 出血性溃疡、 肾衰竭、 AIDS、 合成代谢障碍、 内源性生长素缺乏性矮小 症、 Turner综合症和成人生长激素缺乏等有明显疗效， 对抗衰老治疗也 有明显效果； 目前 rHuGH是治疗矮小症的唯一有效药物。 截止至 2001 年 3月， 美国 FDA批准 rHuGH进入临床研究的适应症有： 严重烧伤的 氮保留强化治疗、短肠综合症（独立用药或与谷氨酰胺联合用药）、 AIDS 相关之生长停滞等。 目前 rHuGH己被批准上市的适应症主要有： 青少年 内源性生长素缺乏性矮小症、 Turner综合症相关之矮小症、 青少年自发 性或器官性生长素缺乏性矮小症、 Prader-Willi 综合症、早产性生长障碍、 AIDS 相关之分解代谢障碍、慢性肾衰竭相关之生长迟滞和成人生长素缺 乏症等。
聚乙二醇（PEG)是一种惰性、 无毒、 可生物降解的有机多聚物， 在 生物技术和制药领域有重要用途。 PEG修饰技术是通过共价结合将 PEG 连接到活性蛋白上。 蛋白质药物经 PEG化后， 其性状有显著改善， 具体 包括药代半衰期延长、 免疫原性降低、 安全性提高、 疗效增强、 给药频 度降低、 药物可溶性和水溶性提高、 蛋白酶酶解抗性增强、 方便药物的 控释等 ( Inada et al. J.Bioact. and Compatible Polymers, 5， 343, 1990; Delgado,et al. Critical Reviews in Therapeutic Drug Carrier Systems, 9， 249, 1992; Katre, Advanced Drug Delivery Systems, 10, 91， 1993和 Davis等的美 国专利 4179337) 。 美国专利 4179337揭示， PEG与酶和胰岛素等蛋白质 结合后， 蛋白质的免疫原性降低的同时蛋白质的细胞学活性明显下降， 但 同时仍保留了原蛋白质一定比例的活性。 这种效应在 G-CSF (Satake-Ishikawa, et al.Cell Structure and Function, 17, 157-160, 1992) 、 IL-2 (Katre, et al. Proc.Natl.Acad.Sci. USA， 84, 1487， 1987)、 TNF-α (Tsutsumi, et al. JpiLj, Cancer Res., 85， 9, 1994)、 EL-6(Inoue, et al. J丄 ab.Clin.Med.， 124, 529, 1994)和 CD4-IgG (Chamow, et al. Bioconj.Chem., 5, 133, 1994) 中均有发 现。
美国专利 5824784利用末端带醛基的 PEG修饰剂， 实现了固定位点 (蛋白质 N-端氨基酸） 单修饰的 PEG-G-CSF。 用 N-羟基琥珀酰亚胺活化 法合成的 PEG-NHS修饰剂能与 G-CSF 的赖氨酸的 ε -氨基形成酰胺键。 PEG-NHS的化学活性高， 选择性较差， 很难获得固定位点单修饰的修饰 产物。 单修饰产物与多修饰产物相比更均一， 有利于分离纯化， 易于大 规模制备时的质量控制和保证批间稳定性。
目前已有多种 PEG化治疗性蛋白质药物应用于临床。如 PEG化腺苷 脱氨酶 （Adagen.RTM, Enzon Pharmaceuticals); PEG化 L-天冬酰胺酶 ( Oncapspar.RTM， Enzon Pharmaceuticals ) ； PEG 化干扰素 alb (PEG-Intron.RTM, Schering-Plough) 和 PEG化干扰素 a2a (Pegasys, Roche); PEG化粒细胞集落刺激因子 （Neulasta.RTM, Amgen)0 药物中 的 PEG部分（或 PEG)在体内的代谢过程已相当清楚， 已证实其是一种 良好的、 安全的、 无副作用的药物改性剂。
能与蛋白质药物结合的 PEG通常需经过衍生，使 PEG两端的一个或 二个端基被化学活化后具有适当的官能团， 该官能团对要结合的药物中 的至少一个官能团具有活性， 能与之形成稳定的共价键。 例如， PEG可 连接到蛋白质肽链中的 Lys残基的 ε-ΝΗ2上， 或连接到蛋白质肽链 Ν端 氨基酸残基的 α- Η2上。 已经用于修饰蛋白质的聚乙二醇通常有三种形 式： 直链分子形式 （ΕΡ 0593868； Yu-Sen Wang et al. Advanced Drug Delivery Reviews, 54： 547-570, 2002; Yu-Sen Wang et al. Biochemistry, 39, 10634-10640, 2000. )、 U形分支的支链分子形式（EP 0809996)和 Y 形分支的支链分子形式（CN1243779C、EP1496076)。欧洲专利 EP0809996 描述了 IFN-α的 PEG化。
. 本领域普遍认为， 经 PEG修饰后， 大多数蛋白质的性质会发生以下 变化： 1.免疫原性与抗原性降低； 2.循环半衰期延长； 3.溶解性增加； 4. 耐蛋白酶水解； 5.生物利用度提高； 6.毒性降低； 7.热稳定性及机械稳定 性增加； 8.等电点、 电泳行为、 动力学性质等改变。 另外， 很重要的一点 是蛋白质经 PEG修饰后会引起细胞学活性的降低， 主要原因为终产品中 引进的基团、包括 PEG以及 PEG和修饰蛋白质之间的连接键所致， 也与 偶联的条件、产生的副产物等有关。 Doris Brugger等（US Patent, Pub.No.： US 2004/0223950 Al )描述了干扰素 a2a的不同修饰位点的双链 UPEG单 位点修饰产物的体外抗病毒活性有明显区别， 其中 Lys31 位点的 UPEG 单位点修饰产物的比活性最高， Lysl21位点的 UPEG单位点修饰产物的 比活性最低， 二者的比活性可相差 5倍。
李伟华等 （中国专利公开号： CN 1477126A) 描述了制备 PEG修饰 生长激素的方法。 该方法优选 pH 6.5-7.0进行生长激素的分叉型 PEG (mPEGn-NHS) 修饰反应， 纯化的生长激素分叉型 PEG单位点修饰物采 用去脑垂体大鼠法测定生物活性。 结果表明， 等量的聚乙二醇生长激素 偶联物 （PEG为双链 PEG-NHS、 分子量为 40kD) 与每天注射的生长激 素的增重效果相当 发明简述
本发明提供了一种制备双链聚乙二醇化生长激素的方法， 包括如下 步骤：
a)在 pH不低于 6.0、 优选不低于 7.0、 优选不低于 8.0、 优选不低于 9.0、 优选不低于 9.5、 优选不低于 10.0、 最优选为 10.5的溶液中将 U型 或 Y型分支的双链聚乙二醇和生长激素优选人生长激素接触， 优选所述 生长激素和双链聚乙二醇的摩尔比为大约 1 : 2；
b) 在适当浓度的 SDS-PAGE、 优选 12% SDS-PAGE中检测 a) 步骤 所得的聚乙二醇单位点修饰产物， 其中所述产物为两条带或以表观分子 量小的条带为主；
c) 分离、 回收所述两条带中表观分子量小的聚乙二醇单位点修饰产 物；
任选地还包括纯化步骤， 优选使用凝胶层析方法如 Q Sepharose FF 层析、 DEAE Sepharose FF层析或 MacroCap SP层析纯化。
在一个优选实施方案中， 本发明提供了一种制备双链聚乙二醇化生 长激素的方法， 其中所述双链聚乙二醇为具有如下结构式（I) 的 Y型聚 乙二醇，
Figure imgf000005_0001
(I)
其中： P^n Pb是相同或不同的聚乙二醇； j 为 1-12 的整数； R^ H、 12 经取代或未经取代的垸基、 取代芳基、 芳垸基或杂垸基； 和：¾分别独 立地是连接基团，其中 Χ, ¾(( Η2)η，Χ2为选自于以下组中的基团：（CH2)n、 (CH2)nOCO、（CH2)nNHCO、 (CH2)nCO, 而 n为 1-10的整数； F 是选自于 以下组中的端基： 羟基、 羧基、 酯基、 酰氯、 酰肼、 马来酰亚胺、 吡啶 二硫化物， 可以与治疗药物或基体上的氨基、 羟基或硫羟基反应形成共 价键。 在一个优选实施方案中， 本发明提供了一种制备双链聚乙二醇化生 长激素的方法， 其中所述 Y型聚乙二醇具有如下结构式 （Π):
Figure imgf000006_0001
(II)
其中 R和 R '为无关的低分子量垸基， 优选 -C4烷基， 最优选甲基； m 和 m'表征聚合度， 为任何整数； m+m'优选 600到 1500; j 为 1-12 的整 数； 为 H、 d-12经取代或未经取代的垸基、 取代芳基、 芳垸基或杂垸 基； F 是选自于以下组中的端基. · '羟基、 羧基、 酯基、 酰氯、 酰肼、 马 来酰亚胺、 吡啶二硫化物， 可以与治疗药物或基体上的氨基、 羟基或硫 羟基反应形成共价键。
在一个优选实施方案中， 本发明提供了一种制备双链聚乙二醇化生 长激素的方法， 其中所述 Y型聚乙二醇具有如下结构式 （III):
Figure imgf000006_0002
(III)
其中 R和 R'为无关的低分子量烷基， 优选 CrC4垸基， 最优选甲基； m 和 m'表征聚合度， 为任何整数； m+m'优选 600到 1500， 最优选 910; 聚 乙二醇的总平均分子量为约 26kD至 60kD， 优选为 40kD; j 为 1-12 的 整数。
在一个优选实施方案中， 本发明提供了一种制备双链聚乙二醇化生 长激素的方法， 其中所述双链聚乙二醇为具有如下结构式 （IV) 的 U型 聚乙二醇，
Figure imgf000007_0001
(IV)
其中， R和 R，为独立无关的低分子量烷基， 优选 -C4垸基； n和 n， 表 征聚合度， 为任何整数； n+n'介于 600-1500之间， 最优选 910; 所述 U 型聚乙二醇平均分子量为约 26kD至 66 kD， 最优选为约 40 kD。
在一个优选实施方案中， 本发明提供了一种制备双链聚乙二醇化生 长激素的方法， 包括如下步骤：
a)在 pH9.0或 10.5的溶液中将下式（III)所示的聚乙二醇和人生长 激素接触， 其中所述人生长激素和双链聚乙二醇的摩尔比为大约 1 : 2；
Figure imgf000007_0002
(III)
其中 R和 R'为无关的低分子量垸基，优选 d- 垸基，最优选甲基； m+m' 为 910; j 为 1-12 的整数； 聚乙二醇的总平均分子量为约 40kD;
b)在 12% SDS-PAGE中检测 a)步骤所得的聚乙二醇单位点修饰产 物， 其中所述产物为两条带；
c)使用凝胶层析方法纯化分离、 回收所述表观分子量小的聚乙二醇 单位点修饰产物； 所述凝胶层析方法选自 Q Sepharose FF层析、 DEAE Sepharose FF层析或 MacroCap SP层析。
本发明还提供了用上述方法制备的聚乙二醇化生长激素， 其中所述 生长激素为从天然来源提取的或通过重组生物技术获得的重组生长激 素， 优选具有 SEQ ID NO: 1所示序列。
在一个优选实施方案中， 本发明提供了用上述方法制备的聚乙二醇 化生长激素，其中所述聚乙二醇化生长激素分子: 为 62kD,如下式（VII) 所示：
Figure imgf000008_0001
(VII)
其中 R和 R'为无关的低分子量垸基，优选 CrC4垸基，最优选甲基； m+m' 为 910; j 为 1-12的整数。
本发明还提供了一种制备聚乙二醇化生长激素制备物的方法， 包括 如下步骤：
a)在 pH不低于 8.0、 优选不低于 9.0、 优选不低于 9.5、 优选不低于 10.0、 最优选为 10.5的溶液中将 U型或 Y型分支的双链聚乙二醇和生长 激素优选人生长激素接触， 优选所述生长激素和双链聚乙二醇的摩尔比 为大约 1 : 2；
b)在适当浓度的 SDS-PAGE、 优选 12% SDS-PAGE中检测 a) 步骤 所得的聚乙二醇单位点修饰产物， 其中所述产物为两条带；
c) 分离、 回收所述聚乙二醇单位点修饰产物；
所述回收的产物是以表观分子量低的聚乙二醇单位点修饰产物为主 的混合物， 其中表观分子量低的聚乙二醇单位点修饰产物的 SDS-PAGE 含量不低于 70%、 优选不低于 80%、 最优选不低于 90%，
任选地还包括纯化步骤， 优选使用凝胶层析方法如 Q Sepharose FF 层析、 DEAE Sepharose FF层析或 MacroCap SP层析纯化。
在一个优选实施方案中， 本发明还提供了一种制备聚乙二醇化生长 激素制备物的方法， 其中所述双链聚乙二醇为具有如下结构式 （I) 的 Y 型聚乙二醇，
Figure imgf000008_0002
(I) 其中： P Pb是相同或不同的聚乙二醇； j 为 1-12 的整数； R^H、 CM2 经取代或未经取代的烷基、 取代芳基、 芳垸基或杂垸基； Χ^ΠΧ2分别独 立地是连接基团，其中 1为(0¾)„， Χ2为选自于以下组中的基团：（CH2)n、 (CH2)nOCO、（CH2)nNHCO、（CH2)nCO， 而 n为 1-10的整数； F 是选自于以 下组中的端基： 羟基、 羧基、 酯基、 酰氯、 酰肼、 马来酰亚胺、 吡啶二 硫化物， 可以与治疗药物或基体上的氨基、 羟基或硫羟基反应形成共价 键。
在一个优选实施方案中， 本发明还提供了一种制备聚乙二醇化生长 激素制备物的方法， 其中所述 Y型聚乙二醇具有如下结构式 （Π) :
ROCH2CH2(OCH2CH2 )m-0-CH2CH:
ROCH2 CH2(0CH2 CH2 )m'-O— CH2-
其中 R和 R '为无关的低分子量垸基， 优选 d-C4烷基， 最优选甲基； m 和 m'表征聚合度，为任何整数； m+m'优选 600到 1500，最优选 910; j 为 1-12 的整数； ^为 11、 CL12经取代或未经取代的烷基、 取代芳基、 芳垸 基或杂烷基； F 是选自于以下组中的端基： 羟基、 羧基、 酯基、 酰氯、 酰肼、 马来酰亚胺、 吡啶二硫化物， 可以与治疗药物或基体上的氨基、 羟基或硫羟基反应形成共价键。
在一个优选实施方案中， 本发明还提供了一种制备聚乙二醇化生长 激素制备物的方法， 其中所述 Y型聚乙二醇具有如下结构式 （ΠΙ):
Figure imgf000009_0001
(III)
其中 R和 R'为无关的低分子量垸基， 优选 CrC4烷基， 最优选甲基； m 和 m'表征聚合度，为任何整数； m+m'优选 600到 1500，最优选 910; j 为 1-12 的整数； 优选聚乙二醇的总平均分子量为约 26 kD至 60 kD， 优选 为 40 kD。
在一个优选实施方案中， 本发明还提供了一种制备聚乙二醇化生长 激素制备物的方法， 其中所述双链聚乙二醇为具有如下结构式 （IV ) 的 U型聚乙二醇，
Figure imgf000010_0001
( IV)
其中 R和 R，为独立无关的低分子量烷基， 优选 CrC4垸基； ！1和11，表征 聚合度， 为任何整数； n+n'介于 600-1500之间， 最优选 910; 所述 U型 聚乙二醇平均分子量为约 26kD至 66 kD， 最优选为约 40 kD。
在一个优选实施方案中， 本发明还提供了一种制备聚乙二醇化生长 激素制备物的方法， 其包括如下步骤：
a) 在 pH 9.0或 10.5的溶液中将下式 （III)所示的聚乙二醇和人生 长激素接触，其中所述人生长激素和双链聚乙二醇的摩尔比为大约 1 : 2；
Figure imgf000010_0002
( III)
其中 R和 R'为独立无关的低分子量垸基，优选 d-C4烷基； m+m'为 910， j 为 1-12 的整数； 聚乙二醇的总平均分子量为约 40 kD;
b )在 12% SDS-PAGE中检测 a)步骤中所得的聚乙二醇单位点修饰 产物；
c )使用凝胶层析方法分离、 回收所述聚乙二醇单位点修饰产物， 所 述凝胶层析方法选自 Q Sepharose FF层析、 DEAE Sepharose FF层析或 MacroCap SP层析，所述回收的产物中表观分子量低的聚乙二醇单位点修 饰产物的 SDS-PAGE含量不低于 70%、 优选不低于 80%、 最优选不低于 90%。
本发明还提供了用上述方法制备的聚乙二醇化生长激素制备物， 其 中所述生长激素为从天然来源提取的或通过重组生物技术获得的重组生 长激素， 优选具有 SEQ ID NO: 1所示序列。 优选地， 所述聚乙二醇化生 长激素制备物中聚乙二醇单位点修饰产物如下式 （VII) 所示：
Figure imgf000011_0001
(VII)
其中 R和 R'为无关的低分子量垸基，优选 CrC4垸基，最优选甲基； m+m' 为 910; j 为 1-12的整数，所述聚乙二醇化生长激素制备物中表观分子量 低的聚乙二醇单位点修饰产物的 SDS-PAGE含量不低于 70%、 优选不低 于 80%、 最优选不低于 90%。
在本发明的一个优选实施方案中， 所述重组人生长激素是人工合成 的或由选自如下一组的表达系统表达： 原核系统如大肠杆菌； 真核酵母 系统如毕赤酵母； 昆虫细胞系统； 和哺乳动物细胞系统如 CHO细胞。
本发明还提供了一种组合物， 其包含药物学有效剂量的上述聚乙二 醇化生长激素或聚乙二醇化生长激素制备物和药物学可接受的载体或赋 形剂， 优选包含甘露醇、 氨基酸、 氯化钠、 醋酸和醋酸钠， 其中氨基酸 优选天冬氨酸、 天冬酰氨、 赖氨酸和甘氨酸。
本发明还提供了上述聚乙二醇化生长激素或聚乙二醇化生长激素制 备物或组合物在制备用于治疗需要用生长激素治疗的疾病和抗衰老治疗 的药物中的应用， 所述需要用生长激素治疗的疾病优选选自矮小症、 烧 伤、 创伤、 骨折、 出血性溃疡、 肾衰竭、 AIDS、 内源性生长素缺乏性矮 小症、 Turner综合症、 合成代谢障碍和成人生长激素缺乏。
本发明还提供了一种治疗患有需要用生长激素治疗的疾病的患者和 抗衰老治疗的方法， 所述方法包括给予所述患者治疗有效量的上述聚乙 二醇化生长激素或聚乙二醇化生长激素制备物或组合物， 其中所述需要 用生长激素治疗的疾病优选选自矮小症、 烧伤、 创伤、 骨折、 出血性溃 疡、 肾衰竭、 AIDS、 内源性生长素缺乏性矮小症、 Turner综合症、 合成 代谢障碍和成人生长激素缺乏。 发明详述
本发明提供了高生物活性的双链 PEG修饰生长激素及其制备方法。 本发明的显著特点是在优化反应条件和分离方法后， 可显著减少生长激 素的 PEG单位点修饰物中低细胞学活性成分的含量。在双链 PEG分子量 为 40kD 的一个实施例中， 低细胞学活性单位点修饰物的特征是在 12% SDS-PAGE分离胶上可与高细胞学活性的单位点修饰物完全分离成 2个 条带， 且低细胞学活性单位点修饰物的表观分子量大于高细胞学活性单 位点修饰物。 以去脑垂体大鼠为动物模型， 以重组人生长激素为阳性对 照， 按《中国药典》 2005版二部附录 ΧΠ P生长激素生物测定法测定最终 制备的高细胞学活性单位点修饰物的体内生物活性。 高细胞学活性单位 点修饰物的生物比活性显著高于普通生长激素， 其表现为普通生长激素 的 1.5倍以上； 食蟹猴药代动力学研究表明，其平均血清药代半衰期比普 通生长激素延长了 20倍以上， 具有长效的作用。
在本发明的一个实施方案中， 在 pH8.0 的条件下进行生长激素的双 链 PEG-NHS修饰反应， 采用 SDS-PAGE电泳检测反应产物， 银染显色。 令人惊奇的是， 生长激素的 PEG单位点修饰产物为 2条主带， 不同于此 前的报道 (Ross Clark, Kenneth 01son,et al. Long-acting growth hormones produced by conjugation with polyethylene glycol. J. Biol.Chem.，271:21969-21977， 1996.李伟华、董建等， 长效生长激素及药物 组合物， 中国专利公开号： CN1477126A) 。 在进一步的实验中， 考察了 ρΗό.0-10.5范围内生长激素的双链 PEG-NHS修饰情况， SDS-PAGE检测 时均发现单位点修饰产物为 2条主带， 并且随反应 pH升高， 表观分子量 小的条带含量相应升高， 至 pH 10.0， 单位点修饰产物基本以表观分子 量小的条带为主。
在本发明一个优选的实施方案中， 采用适宜的凝胶层析纯化工艺分 别制备 ρΗΙΟ.5和 pH6.0条件下的重组人生长激素的 PEG单位点修饰物纯 品。 采用分离胶浓度为 12%的 SDS-PAGE检测， 银染显色。 pH6.0条件 下的重组人生长激素的 PEG单位点修饰物纯品为明显的双带； ρΗΙΟ.5条 件下的重组人生长激素的 PEG单位点修饰物纯品以表观分子量小的条带 为主， 其 SDS-PAGE含量不低于 80%; 均只检出微量底物蛋白 （不超过 0.5%) 。 MALDI-TOF MS检测确证该 2种 pH条件下的修饰产物均为生 长激素的 PEG单位点修饰物； 细胞学活性检测表明， ρΗΙΟ.5条件下的单 位点修饰物的细胞学活性显著高于 pH6.0条件下的单位点修饰物， 前者 的细胞学比活性约为后者的 2倍。
在本发明一个优选的实施方案中， 经 Q Sepharose FF 层析纯化和 MacroCap SP层析纯化等步骤制备 pH6.0条件下重组人生长激素的 PEG 修饰产物中表观分子量大的单位点修饰产物纯品。 MALDI-TOF MS检测 确证该重组人生长激素 PEG修饰物为 PEG单位点修饰物；细胞学活性检 测表明，其细胞学比活性显著低于 ρΗΙΟ.5条件下的重组人生长激素 PEG 单位点修饰物（表观分子量小）纯品， 后者的细胞学比活性可达前者的 3 倍左右。
在本发明进一步的实施方案中， 按 《中国药典》 2005年版附录 ΧΠ P 生长激素生物测定法， 以重组人生长激素为阳性对照， 采用去脑垂体大 鼠法检测 ρΗΙΟ.5条件下重组人生长激素的 PEG-NHS 40kD单位点修饰物 的体内生物学活性。 重组人生长激素每天给药一次， 连续给药 6次； 重 组人生长激素 PEG单位点修饰物按与重组人生长激素 6次给药剂量总和 一致的剂量一次性给药。 该重组人生长激素 PEG单位点修饰物的生物学 活性显著高于重组人生长激素，可达后者生物学比活性的 1.5倍以上， 其 药理学具有长效的特点。 食蟹猴药代动力学研究表明， 该重组人生长激 素 PEG单位点修饰物的药代半衰期较普通重组人生长激素延长了 20倍 以上。
本发明采用分支型 （U型分支和 Y型分支） PEG衍生物修饰生长激 素。 本发明所采用的 Y型分支 PEG衍生物是一种新型的分支型 PEG衍 生物， 其结构不同于直链 PEG和 U型分支 PEG, 其与 U型分支 PEG的 主要区别在于:本发明采用的 Y型 PEG衍生物的 2条 PEG分支链通过 N 原子连接在一起， 而 U型 PEG衍生物的 2条 PEG分支链通过 C原子连 接在一起。本发明所述 Y型和 U型 PEG修饰主要发生在蛋白质或肽的 N 末端游离的 α-氨基和 Lys侧链的 ε-氨基上。 Υ型 PEG衍生物分子组成示 于下式 (1)：
Figure imgf000014_0001
(I)
其中： P H Pb是相同或不同的聚乙二醇； j 为 1-12 的整数； Ri为 H、 C1-12 经取代或未经取代的垸基、 取代芳基、 芳垸基或杂垸基； χ^η χ2分别独 立地是连接基团，其中 X,为 (CH2)n, X2为选自于以下组中的基团：（CH2)n、 (CH2)nOCO、（CH2)n HCO、 (CH2)nCO, 而 n为 1-10的整数； F 是选自于 以下组中的端基： 羟基、 羧基、 酯基、 酰氯、 酰肼、 马来酰亚胺、 吡啶 二硫化物， 可以与治疗药物或基体上的氨基、 羟基或硫羟基反应形成共 价键。
在本发明一个优选的实施方案中， 所述 Y形 PEG衍生物结构式中 ?&和？1)可为相同或不同的聚乙二醇， 如下式 (Π)所示：
Figure imgf000014_0002
(Π)
其中 R和 R，为无关的低分子量烷基， 优选 -C4垸基， 最优选甲基； m 和 m，表征聚合度， 为任何整数； m+m'优选 600到 1500， 最优选 910; 为11、 d.12经取代或未经取代的烷基、 取代芳基、 芳烷基、 或杂垸基； j 为 1-12 的整数。 F 是选自于以下组中的端基： 羟基、 羧基、 酯基、 酰 氯、 酰肼、 马来酰亚胺、 吡啶二硫化物， 可以与治疗药物或基体上的氨 基、 羟基或巯基反应形成共价键。 优选地， 其中聚乙二醇的总平均分子 量为约 26kD— 60kD， 最优选为约 40kD。
在一个实施方案中， 本发明提供了一种聚乙二醇化生长激素， 其具 有如下式 （VI) 结构：
Figure imgf000015_0001
(VI)
其中： R和 R，为无关的低分子量烷基，优选 CrC4垸基，最优选甲基； j 为 1-12的整数； m和 m，表征聚合度， 为任何整数； m+m，优选 600到 1500; ^为11、 C 12经取代或未经取代的烷基、 取代芳基、 芳烷基、 或杂烷基; F是选自于以下组中的端基： 羟基、 羧基、 酯基、 酰氯、 酰肼、 马来酰亚 胺、 吡啶二硫化物， 可以与治疗药物或基体上的氨基、 羟基或巯基反应 形成共价键。在本发明一个优选的实施方案中， 一种 Y型 PEG衍生物分 子 （YPEG-NHS) 结构式如下式 （III) 所示：
Figure imgf000015_0002
其中 R和 R，为无关的低分子量焼基，优选 CrC4烷基，最优选甲基； j 为
1-12的整数； m和 m，表征聚合度， 为任何整数； m+m，优选 600到 1500， 最优选为 910。
在本发明另一个优选的实施方案中， 一种 U 型 PEG衍生物分子 (UPEG-NHS) 结构式如下式 （IV) 所示：
Figure imgf000015_0003
式中， R和 R，为独立无关的低分子量垸基， 优选 垸基； n和 n'表征 聚合度， 为任何整数； n+n，介于 600-1500之间， 最优选 910; PEG平均 分子量为约 26kD-66kD， 最优选为约 40kD。
在本发明的一个实施方案中， 为了获得 YPEG或 UPEG修饰的 GH, 首先将 YPEG 和 UPEG 经活化的衍生物如聚乙二醇琥珀酰亚胺酯 (PEG-NHS) ， 通过亲核取代反应， 将 PEG部分共价结合在蛋白质的氨 基 （-NH2) 上， 包括蛋白质 N端的 a-氨基和赖氨酸残基的 ε-氨基。 GH 与 YPEG-NHS反应生成 YPEG-GH的反应方程式如下：
屮, N—GH
Figure imgf000016_0001
Figure imgf000016_0002
GH与 UPEG-NHS反应生成 UPEG-GH的反应方程式如下:
Figure imgf000016_0003
优选地，聚乙二醇的总平均分子量为约 26kD- 60kD，最优选为 40kD。 在进一步优选的实施方案中， 本发明的聚乙二醇化生长激素具有如 下 1式 （VII) 结口构1 J：
Figure imgf000016_0004
(VII) 其中 R和 R'为无关的低分子量垸基，优选 d-C4垸基， 最优选甲基； j 为 1-12的整数； m和 m，表征聚合度， 为任何整数； m+m，优选 600到 1500。 该结构中， Y分支 PEG通过单位点结合到生长激素分子上。 m和 m，可为 相同或不同整数。 上式中的 YPEG-GH的分子量主要取决于聚合度 m和 mO m+m' 优选 600到 1500， 对应 YPEG的平均分子量为约 26kD到约 66kD; 其中 m+m'优选 795到 1030， 对应 YPEG平均分子量为约 35kD 到 45kD; m+m'特别优选 885到 1030，对应 YPEG平均分子量为约 39kD 至 lj 45kD; m+m'最优选 910， 对应 YPEG平均分子量为约 40kD。 m和 m， 的比值范围可以为 0.5到 1.5， 优选 0.8到 1.2。
任选地， 本发明的生长激素可以为从天然来源提取的或通过重组生 物技术获得的生长激素。 优选地， 所述生长激素为从天然来源提取的或 通过重组生物技术获得的具有 SEQ ID ΝΟ: 1所示序列的人生长激素。 更 优选地， 所述人生长激素是重组人生长激素。 生长激素可以是人工合成 的， 也可以是原核系统如大肠杆菌 (E. Coli 表达的， 也可以是真核酵母 系统如毕赤酵母 Pichia pastoris 表达的， 也可以是其它昆虫细胞系统 或哺乳动物细胞系统如 CHO表达的。制备天然或重组生长激素的方法以 及生长激素和其 PEG修饰产物的活性检测方法为本领域现有技术。
本发明所述 YPEG-GH和 UPEG-GH与 GH的临床用途相同，均适用 于治疗矮小症、 烧伤、 创伤、 骨折、 出血性溃疡、 肾衰竭、 AIDS、 合成 代谢障碍、 成人生长激素缺乏等和抗衰老治疗。 本发明的 YPEG-GH和 UPEG-GH可以以组合物的形式给予患者，所述组合物中包含药物学有效 剂量的 YPEG-GH或 UPEG-GH和药物学可接受的载体或赋形剂。 因此， 本发明另一方面提供了一种组合物 Γ其包含药物学有效剂量的本发明的 聚乙二醇化生长激素和药物学可接受的载体或赋形剂。 本发明使用的药 物学上可接受的载伴包括对于以所用剂量和浓度与其接触的细胞或哺乳 动物无毒的药用上可接受的载体、 赋形剂、 或稳定剂。 通常生理学上可 接受的载体是含水的 pH缓冲溶液。生理学上可接受的载体的例子包括诸 如磷酸盐、 柠檬酸盐、 和其他有机酸在内的缓冲液； 包括抗坏血酸在内 的抗氧化剂； 低分子量（不超过 10个残基） 多肽； 诸如血清白蛋白、 明 胶、 或免疫球蛋白等蛋白质； 诸如聚乙烯吡咯烷酮等亲水性多聚体； 诸 如甘氨酸、 天冬氨酸、 谷氨酰胺、 天冬酰胺、 精氨酸或赖氨酸等氨基酸； 单糖包括葡萄糖和甘露糖、 二糖或糊精等其他糖类； 诸如 EDTA等螯合 剂； 诸如甘露醇或山梨醇等糖醇； 诸如钠等成盐反离子； 和 /或诸如 TWEEN、 聚乙二醇、 和 PLURONICS等非离子表面活性剂。 赋形剂优选 无菌且一般不含不良物质。这些组合物可通过常规的灭菌技术进行灭菌。 在本发明的一个实施方案中， 所述组合物其进一步包含甘露醇、 氨基酸、 氯化钠、 醋酸和醋酸钠， 其中氨基酸优选赖氨酸、 天冬氨酸、 天冬酰氨 和甘氨酸。
在另一方面， 本发明还提供了本发明的聚乙二醇化生长激素或包含 发明的聚乙二醇化生长激素的组合物在制备用于治疗需要用生长激素治 疗的疾病和抗衰老治疗的药物中的应用。 优选地， 所述需要用生长激素 治疗的疾病选自矮小症、烧伤、创伤、骨折、出血性溃疡、肾衰竭、 AIDS, 内源性生长素缺乏性矮小症、 Turner综合症、 合成代谢障碍和成人生长 激素缺乏等。 附图说明
图 1： pH8.0条件下 rHuGH的 YPEG-NHS 40kD或 UPEG-NHS 40kD 修饰反应样非还原型 SDS-PAGE电泳结果， 分离胶浓度 12%， 银染显色。 泳道 1 : marker, LMW， GE Healthcare; 泳道 2: rHuGH的 YPEG-NHS 修饰反应样， 反应 pH8.0， 上样量 2μβ; 泳道 3: rHuGH的 YPEG-NHS 修饰反应样， 反应 pH8.0， 上样量 5 g; 泳道 4: rHuGH的 UPEG-NHS 修饰反应样， 反应 pH8.0， 上样量 5μ§。
图 2:不同 ρΗ条件下 rHuGH的 YPEG-NHS 40kD修饰反应样非还原 型 SDS-PAGE电泳结果， 分离胶浓度 12%， 银染显色。 泳道 1 : rHuGH 的 YPEG-NHS修饰反应样， 反应 pH6.0; 泳道 2: rHuGH的 YPEG-NHS 修饰反应样， 反应 pH7.0; 泳道 3: rHuGH的 YPEG-NHS修饰反应样， 反应 pH8.0; 泳道 4: rHuGH的 YPEG-NHS修饰反应样， 反应 pH9.0; 泳道 5: rHuGH的 YPEG-NHS修饰反应样， 反应 pH9.5; 泳道 6: rHuGH 的 YPEG-NHS修饰反应样， 反应 ρΗΙΟ.Ο; 泳道 7: rHuGH的 YPEG-NHS 修饰反应样， 反应 pH10.5; 泳道 8: marker, LMW, GE Healthcare。 各 样品上样量均为 5 g。
图 3: 不同 pH条件下 rHuGH的 UPEG-NHS修饰反应样非还原型 SDS-PAGE电泳结果， 分离胶浓度 12%， 银染显色。 泳道 1 : rHuGH的 UPEG-NHS修饰反应样， 反应 pH6.0; 泳道 2: rHuGH的 UPEG-NHS修 饰反应样， 反应 pH7.0; 泳道 3: rHuGH的 UPEG-NHS修饰反应样， 反 应 pH8.0; 泳道 4: rHuGH的 UPEG-NHS修饰反应样， 反应 pH9.0; 泳 道 5: rHuGH的 UPEG-NHS修饰反应样， 反应 pH9.5; 泳道 6: rHuGH 的 UPEG-NHS修饰反应样， 反应 ρΗΙΟ.Ο; 泳道 7: rHuGH的 UPEG-NHS 修饰反应样， 反应 pH10.5; 泳道 8: marker, LMW, GE Healthcare。 各 样品上样量均为 5μ§。
图 4: ρΗ6.0 和 ρΗ10.5 条件下 rHuGH 的 YPEG-NHS 40kD 或 UPEG-NHS 40kD单位点修饰物纯品非还原型 SDS-PAGE电泳结果，分离 胶浓度 12%， 银染显色。 泳道 1 : UPEG-rHuGH U10.5， 上样量 lO g; 泳 道 2: UPEG-rHuGH U10.5, 上样量 2 g; 泳道 3: UPEG-rHuGH U6.0, 上样量 lO g; 泳道 4: UPEG-rHuGH U6.0, 上样量 2 g; 泳道 5: marker, LMW, GE Healthcar; 泳道 6: YPEG-rHuGH Y10.5, 上样量 10 g; 泳道 7： YPEG-rHuGH Y10.5, 上样量 2 g; 泳道 8: YPEG-rHuGH Y6.0, 上样 量 l(^g; 泳道 9: YPEG-rHuGH Y6.0, 上样量 2 g; 泳道 10: rHuGH, 上样量 lOOng; 泳道 11 : rHuGH, 上样量 50ng。
图 5: pH6.0和 ρΗ10.5条件下 rHuGH的 UPEG-NHS 40kD单位点修 饰物纯品细胞学活性检测结果， 2块平行板。
图 6: pH6.0、 pH10.5条件下 rHuGH的 YPEG-NHS 40kD单位点修饰 物纯品细胞学活性检测结果， 2块平行板。
图 7: pH6.0、 pH9.0、 pH 10.5条件下 rHuGH的 YPEG-NHS 40kD单 位点修饰物纯品和 UPEG-NHS 40kD单位点修饰物纯品 MALDI-TOF MS 分子量检测结果。 a: YPEG-rHuGH, Y6; b: YPEG-rHuGH, Y9; c: YPEG-rHuGH, Y10.5; d: YPEG-rHuGH, Y6-1 ; e: UPEG-rHuGH, U6; f: UPEG-rHuGH, U9; g: UPEG-rHuGH, U10.5 ; h: UPEG-rHuGH, U6-1 ; i: YPEG-NHS, 40kD; j: UPEG-NHS, 40kD; k: Protein Calibrate Standard II , BRUKER; 1： rHuGH; m: Protein Calibrate Standard I ， BRUKER。
图 8: pH6.0条件下 rHuGH的 PEG-NHS 40kD修饰产物之表观分子量 大的 PEG单位点修饰物纯品与 ρΗΙΟ.5条件下 rHuGH的 PEG-NHS 40kD单 位点修饰物纯品非还原型 SDS-PAGE检测结果，分离胶浓度 12%，银染显 色。 泳道 1 : YPEG-rHuGH Y10.5， 上样量 2 g; 泳道 2: YPEG-rHuGH Y6.0-1 , 上样量 2μβ; 泳道 3: UPEG-rHuGH U10.5, 上样量 2 g; 泳道 4: UPEG-rHuGH U6.0-l , 上样量 2 g; 泳道 5: rHuGH, 上样量 50ng; 泳道 6： rHuGH, 上样量 lOOng; 泳道 7: marker, LMW, GE Healthcare; 泳 道 8: YPEG-rHuGH Yl 0.5, 上样量 l(^g; 泳道 9: YPEG-rHuGH Y6.0-1 , 上样量 lO g; 泳道 10: UPEG-rHuGH U10.5, 上样量 l(^g; 泳道 11 : UPEG-rHuGH U6.0-l , 上样量 10 g。
图 9: pH6.0条件下 rHuGH的 PEG-NHS 40kD修饰产物之表观分子量 大的 PEG单位点修饰物纯品 （Y6-l、 U6-1 )和 ρΗ10.5条件下 rHuGH的 PEG-NHS 40kD单位点修饰物纯品 （Y10.5、 U10.5) 还原型 SDS-PAGE表 观分子量检测结果。 泳道 1 : YPEG-rHuGH Y6-l+YPEG-rHuGH Y10.5, 各 25ng;泳道 2: YPEG-rHuGH Y6-1 , 50ng;泳道 3: YPEG-rHuGH Yl 0.5, 50ng; 泳道 4、 6： 空白； 泳道 5: marker, HMW, GE Healthcare; 泳道 7： UPEG-rHuGH U6-l+UPEG-rHuGH U10.5， 各 25ng ; 泳道 8 : UPEG-rHuGH U6-1 , 50ng; 泳道 9: UPEG-rHuGH Ul 0.5, 50ng。
图 10 : 食蟹猴单次皮下注射分别给予 ΟΟμ Ι^1 rHuGH 和 YPEG-rHuGH (Y10.5 ) 的平均血清药物浓度 -时间曲线比较。 具体实施方式
本发明通过下述实施例进一步阐明， 但任何实施例或其组合不应当 理解为对本发明的范围或实施方式的限定。 本发明的范围由所附权利要 求书限定， 结合本说明书和本领域一般常识， 本领域普通技术人员可以 清楚地明白权利要求书所限定的范围。 实施例 1
重组人生长激素的 U型和 Y型分支 PEG修饰 分别取 200mg UPEG-NHS和 YPEG-NHS (平均分子暈 40kD， 等臂； 批号分别为 ZZ004P182、 ZZ004P167) (北京键凯科技有限公司） 各 1 份， 分别溶解于 2ml 2mM HC1 (广东光华化学厂有限公司） ； 分别加入 50mg的 rHuGH (厦门特宝生物工程股份有限公司）和 50mM硼酸 /硼砂 缓冲液 (pH8.0) (中国医药集团上海化学试剂公司）使反应总体积为 10ml。 该反应体系中， rHuGH反应终浓度为 5mg/ml， rHuGH与 PEG-NHS反应 摩尔比约为 1 : 2。 振荡条件下 <10°C温浴 2h， 加入冰乙酸 （汕头市西陇 化工厂） 使 pH<4.0终止反应。 取样进行 SDS-PAGE电泳， 银染显色。 SDS-PAGE电泳结果示于图 1。 由图 1电泳结果可见， pH8.0条件下的修 饰产物主带为双带， UPEG-NHS和 YPEG-NHS修饰反应样的 SDS-PAGE 电泳行为一致。
实施例 2
不同 pH条件下重组人生长激素的 U型和 Y型分支 PEG修饰 分别取 200mg UPEG-NHS和 YPEG-NHS (平均分子量 40kD， 等臂； 批号分别为 ZZ004P182、 ZZ004P167) (北京键凯科技有限公司） 各 1 份， 分别溶解于 2ml 2mM HC1 (广东光华化学厂有限公司） ； 分别加入 50mg的 rHuGH (厦门特宝生物工程股份有限公司）和相应的缓冲液， 使 反应总体积为 10ml。反应 pH 6.0、7.0和 8.0采用相应 pH值的 lOmM PBNa 缓冲液 （中国医药集团上海化学试剂公司） ， 反应 pH 9.0、 9.5、 10.0和 10.5采用相应 pH值的 50mM硼砂缓冲液 （中国医药集团上海化学试剂 公司）。该反应体系中， rHuGH反应终浓度为 5mg/ml， rHuGH与 PEG-NHS 反应摩尔比约为 1 : 2。 振荡条件下 <10°C温浴 2h， 加入冰乙酸 （汕头市 西陇化工厂）使 pH<4.0终止反应。取样进行 SDS-PAGE电泳，银染显色； 采用凝胶成像系统 （型号： FR-200, 上海复日科技有限公司） 分析电泳 结果。 SDS-PAGE电泳结果示于图 2、 图 3， 凝胶成像系统分析结果见表 1。 由电泳结果可见， pH6.0-9.5条件下的修饰产物主带均为明显的双带， 并且随着反应 pH 的升高， 表观分子量小的主带含量相应增加； ρΗΙΟ.Ο 和 10.5条件下的修饰产物基本以表观分子量小的条带为主。 UPEG-NHS 和 YPEG-NHS修饰反应样的 SDS-PAGE电泳行为一致。
表 1. 不同 pH条件下重组人生长激素的 U型和 Y型分支 PEG修饰物 SDS-PAGE结 果凝胶成像系统分析结果
Figure imgf000021_0001
注： 含量指 rHuGH的 PEG单位点修饰产物之条带 1 (表观分子量大） 和条带 2 (表观分子量小） 之间的相对百分含量。 实施例 3
pH6.0、 pH9.0和 10.5条件下重组人生长激素的 U型和 Y型分支 PEG单 位点修饰产物的制备及细胞学活性和分子量检测
1、 修饰反应
分别取 1200mg UPEG-NHS和 YPEG-NHS (平均分子量 40kD,等臂； 批号分别为 ZZ004P182、 ZZ004P167) (北京键凯科技有限公司） 各 3 份， 分别溶解于 12ml 2mM HCl (广东光华化学厂有限公司） ； 分别加入 300mg的 rHuGH (厦门特宝生物工程股份有限公司） 和 50mM硼砂缓 冲液（pH10.5)或 50mM硼砂 /硼酸缓冲液（pH9.0)或 10mM PBNa(pH6.0) (中国医药集团上海化学试剂公司 )—使反应总体积为 60ml。该反应体系中， rHuGH反应终浓度为 5mg/ml， rHuGH与 PEG-NHS反应摩尔比约为 1 : 2， 反应 pH分别为 10.5、 9.0和 6.0， 振荡条件下 <10°C温浴 2h， 加入冰乙酸 (汕头市西陇化工厂） 使 pH<4.0终止反应。 取样进行 SDS-PAGE电泳， 银染显色。
2、 纯化制备
2.1 Q Sepharose FF层析纯化
rHuGH的 PEG修饰反应样用超纯水稀释 3倍， 分别将稀释样的 pH 值用 NaOH或 HC1调至 9.0。
2.1.1 rHuGH PEG修饰反应样 （pH6.0) Q Sepharose FF层析纯化
层析柱体 （上海锦华层析设备厂） 规格为 O18mmx400mm， Q Sepharose FF填料（GE Healthcare)装填规格为 <D18mmx240mm， 柱床体 积 （CV) 为 61ml。 Q Sepharose FF层析柱用 0.5M NaOH 5ml/minx30min 在位清洗， ddH20 5ml/min洗脱 3CV， lM NaCl 5ml/min洗脱 3CV再生， 20mM硼砂 /硼酸 -17mM NaCl (pH 9.0， A液） 5ml/min洗脱 5CV。 rHuGH 的 PEG修饰反应超纯水稀释样按 3ml/min流速上样， 洗脱液检测波长 280nm (AKTA Basic 100, GE Healthcare )。 A液 5ml/min洗脱至第 1个峰 完全洗出； 换 20mM硼砂 /硼酸- lOOmM NaCl (pH 9.0, B液）， 5ml/min 洗脱至第 2个峰完全洗出； 换 20mM硼砂 /硼酸 -200mM NaCl (pH 9.0， C 液）， 5ml/min洗脱至第 3个峰完全洗出。 收集第 2个峰样品即为目的样。 用 5K超滤器（Millipore, 聚醚砜材质）将目的样的缓冲体系超滤替换成 20mM硼砂 /硼酸 （pH 9.0)。
2.1.2 rHuGH PEG修饰反应样 （pH9.0和 10.5 ) Q Sepharose FF层析纯化 层析柱体 （上海锦华层析设备厂） 规格为 （D18mmx400mm， Q Sepharose FF填料（GE Healthcare)装填规格为 O18mmx240mm， 柱床体 积 （CV) 为 61ml。 Q Sepharose FF层析柱用 0.5M NaOH 5ml/minx30min 在位清洗， ddH20 5ml/min洗脱 3CV， 1M NaCl 5ml/min洗脱 3CV再生， 20mM硼砂 /硼酸- 17mM NaCl (pH 9.0， A液） 5ml/min洗脱 5CV。 rHuGH 的 PEG修饰反应超纯水稀释样按 3ml/min流速上样， 洗脱液检测波长 280nm (AKTA Basic 100, GE Healthcare )。 A液 5ml/min洗脱至第 1个峰 完全洗出； 换 20mM硼砂 /硼酸- 40mM NaCl (pH 9.0， B液）， 5ml/min洗 脱至第 2个峰完全洗出； 换 20mM硼砂 /硼酸- lOOmM NaCl (pH 9.0， C 液）， 5ml/min洗脱至第 3个峰完全洗出；换 20mM硼砂 /硼酸 -200mM NaCl (pH 9.0, D液）， 5ml/min洗脱至第 4个峰完全洗出。 收集第 3个峰样品 即为目的样。 用 5K超滤器（Millipore, 聚醚砜材质）将目的样的缓冲体 系超滤替换成 20mM硼砂 /硼酸 （pH 9.0)。
2.2 DEAE Sepharose FF层析纯化
层析柱体 （上海锦华层析设备厂） 规格为 D18mmx400mm， DEAE Sepharose FF 填料 （ GE Healthcare ) 装填规格为 <D18mmx235mm， lCV=60ml。
DEAE Sepharose FF层析柱用 0.5M NaOH 5ml/minx30min在位清洗， ddH20 5ml/min洗脱 3CV， 1M NaCl 5ml/min洗脱 3CV再生， 20mM硼砂 /硼酸（pH 9.0, A液） 5ml/min洗脱 3CV。 PEG-rHuGH的 Q Sepharose FF 纯化超滤替换样按 3ml/min流速上样， A液 5ml/min洗脱 3CV， 20mM硼 砂 /硼酸 -30mM NaCl (pH 9.0， B液） 5ml/min洗脱 6CV; 换 20mM硼砂 /硼酸 -lOOmM NaCl (pH 9.0, C液）， 5ml/min洗脱至第 1、 2峰完全洗出。 洗脱液检测波长 280nm (AKTA Basic 100， GE Healthcare )。 收集第 2峰 样品即为目的样。 用 5K超滤器（Millipore, 聚醚砜材质）将目的蛋白样 的缓冲体系超滤替换成 5mM PBNa (pH 8.5 ) 并适当浓缩。
2.3 Q Sepharose FF层析精细纯化
层析柱体 （上海锦华层析设备厂） 规格为 0>25mmx400mm， Q Sepharose FF 填料 （ GE Healthcare ) 装填规格为 25mmx200mm， lCV=98ml。
Q Sepharose FF层析柱用 0.5M NaOH 10ml/minx30min在位清洗， dd¾0 lOml/min洗脱 3CV, 1M NaCl lOml/min洗脱 3CV再生， 5mM PBNa (pH 8.5, A液） lOml/min洗脱 3CV。 PEG-rHuGH的 DEAE Sepharose FF 纯化超滤替换样按 6ml/min流速上样， A液 10ml/min洗脱 3CV;换 5mM PBNa-90mM NaCl (pH 8.5, B液）， lOml/min洗脱至第 1个峰完全洗出； 换 5mM PBNa-300mM NaCl (pH 8.5, C液）， lOml/min洗脱至第 2个峰 完全洗出。 洗脱液检测波长 280nm (AKTA Basic 100， GE Healthcare )0 收集第 1个峰样品即为目的样。 用 5K超滤器 （Millipore, 聚醚砜材质） 将目的样的缓冲体系超滤替换成 3mM NaAc/HAc- 7mM NaCl- 5mM Lys ( pH 5.0 ) , 补加甘露醇至终浓度 45mg/ml， 0.2μπι 过滤除菌； 取样 SDS-PAGE电泳， 银染显色； 余样- 70°C冻存。 pH6.0修饰反应产物命名 为 Y6或 U6， 其中表观分子量大的条带命名为 Y6-1或 U6-1 , 表观分子 量小的条带命名为 Y6-2或 U6-2; pH9.0修饰反应产物命名为 Y9或 U9; ρΗΙΟ.5修饰反应产物命名为 Y10.5或 U10.5。
SDS-PAGE电泳结果示于图 4。 由电泳结果可见， pH6.0修饰反应产 物为明显的双带； ρΗΙΟ.5修饰反应产物以表观分子量小的条带为主， 其 SDS-PAGE含量不低于 80%。
3、 细胞学活性检测 '
以 GH 国家标准品为对照， 采用 HuGH依赖型大鼠淋巴瘤细胞株 Nb2-l l检测 PEG-rHuGH各样品的细胞学活性。
Nb2-l l 细胞稀释至终浓度 5xl04cell/ml。 GH 国家标准品 （批号： 35-20002, lmg/ml/支， 3IU/支； 购自中国药品生物制品检定所） 预稀释 至 100ng/ml (0.0003IU/ml), PEG-rHuGH各待检品根据预实验结果预稀 释至 0.0003IU/ml; 在预稀释的基础上， 各样品再按倍半梯度稀释后再行 检测。 样品活性计算公式如下：
待检样品活性 (IU / ml)=标准品活性 X X
Figure imgf000024_0001
其中： 0^为待检样品相当于标准品半效量的稀释倍数
c2为标准品半效稀释倍数
01为待检样品预稀释倍数 D2为标准品预稀释倍数
检测方法：
( 1 ) 取对数生长期细胞， 反复吹打、 离心清洗； 用稀释液重悬细胞， 调整细胞浓度至 5xl04cell/ml。
(2) 各待检品预稀释样分别在细胞板 （96 孔板， Corning) 上做两倍 梯度稀释， 共做 10个梯度， 每个梯度做复孔， 50μ1/孔。 阳性对照同法做 8个梯度。 以稀释液为阴性对照。
(3 ) 按 ΙΟΟμΙ/孔加入细胞， 置二氧化碳培养箱 37°C培养约 70小时； 按 30μ1/孔加入 AlamarBlue™溶液 （BioSource), 震荡混匀 1分钟； 置二 氧化碳培养箱 37°C孵育 5 小时。 室温振荡 5 分钟， 读板 （激发光波长 530nm, 发射波长 590nm)。
(4)采用四参数回归法制作标准品曲线和待测样品曲线。 根据标准品 曲线和待测样品曲线方程计算出各供检品的效价。
细胞学活性检测结果见表 2和图 5、 图 6， 每种样品同步检测 2个平 行样。 rHuGH的 YPEG-NHS pH6.0 .修饰产物 （Y6) 的细胞学比活性为
Figure imgf000025_0001
ρΗ Ο修饰产物（Y9)的细胞学比活性为
ρΗ10.5修饰产物 (Y10.5 ) 的细胞学比活性为 Z.i^xli^IU/mg; Y10.5的 细胞学比活性约为 Y6的 2倍。 rHuGH的 UPEG-NHS pH6.0修饰产物（U6) 的细胞学比活性为 8.85xl(T2IU/mg， pH9.0修饰产物（U9) 的细胞学比活 性为 l^Sxlt^IU/mg; pH10.5 修饰产物 （U10.5 ) 的细胞学比活性为 1.82xlO-1IU/mg; U10.5的细胞学比活性约为 U6的 2倍。 随着修饰反应 pH值的提高， PEG单位点修饰产物（2条主带）的细胞学活性相应提高。
表 2.YPEG-rHuGH和 UPEG-rHuGH各样品细胞学活性检测结果 *
Figure imgf000025_0002
注： * 以 GH国家标准品为标准。 标准品批号： 35-20002, lmg/ml/支， 3IU/支， 购自中国药品生 物制品检定所。
4、 MALDI-TOF MS分子量检测
采用德国 BRUKER公司 Autoflex III TOF/TOF质谱仪， MALDI-TOF MS法测定 PEG-rHuGH各样品的分子量。基质采用芥子酸（SA，C„ri1205， MW 224.22； 批号 2006 236870 002， BRUKER), 蛋白分子量标准品采用 BRUKER公司之 Protein Calibration Standard I (Part No.206355)和 Protein Calibration Standard II ( Part No.207234 ) , 分析软件为 flexAnalysis Ver.3.0.54.0.。 结果示于图 7。
rHuGH的 YPEG-NHS pH6.0修饰产物（Y6)、 pH9.0修饰产物（Y9) 和 ρΗ10.5修饰产物（Y10.5)的 MS分子量均在 62012道尔顿士 10%的范 围内，与 YPEG单位点修饰 rHuGH的理论分子量一致（ YPEG-NHS的分 子量为 40kD士 10%)， 说明 Y6、 Υ9和 Y10.5均为 rHuGH的 YPEG单位 点修饰物。 rHuGH的 UPEG-NHS pH6.0修饰产物（U6)、 pH9.0修饰产物 (U9)和 pH10.5修饰产物（U10.5)的 MS分子量均在 62012道尔顿 ± 10% 的范围内， 与 UPEG单位点修饰 rHuGH的理论分子量一致（UPEG-NHS 的分子量为 40kD± 10%)， 说明 U6、 U9和 U10.5均为 rHuGH的 UPEG 单位点修饰物。
实施例 4
PH6.0条件下重组人生长激素 U型和 Y型分支 PEG修饰产物中表观分子 量大的单位点修饰产物 （Y6-l、 U6-1 ) 的制备及分子量和细胞学活性检测
1、 修饰反应
分别取 1200mg UPEG-NHS和 YPEG-NHS (平均分子量 40kD，等臂； 批号分别为 ZZ004P182、 ZZ004P167) (北京键凯科技有限公司） 各 2 份， 分别溶解于 12ml 2mM HCl (广东光华化学厂有限公司） ； 分别加入 300mg 的 rHuGH (厦门特宝生物工程股份有限公司） 和 10mM PBNa (pH6.0) (中国医药集团上海化学试剂公司） 使反应总体积为 60ml。 该 反应体系中， rHuGH反应终浓度为 5mg/ml， rHuGH与 PEG-NHS反应摩 尔比约为 1 : 2, 反应 pH为 6.0。 振荡条件下 <10°C温浴 2h， 加入冰乙酸 (汕头市西陇化工厂） 使 pH<4.0终止反应。
2、 表观分子量大的 PEG单位点修饰产物 （Y6-l、 U6-1 ) 的纯化制备 2.1 Q Sepharose FF层析纯化 rHuGH的 PEG修饰反应样（反应 pH 6.0)用超纯水稀释 3倍， 分别 用 NaOH调 pH至 9.0。
层析柱体 （上海锦华层析设备厂） 规格为 0>25mmx500mm， Q Sepharose FF ±真料 ( GE Healthcare ) 装填规格为 0>25mmx310mm， lCV=152ml0 Q Sepharose FF层析柱用 0.5M NaOH 10ml/minx30min在位 清洗， ddH20 lOml/min洗脱 3CV， lM NaCl 10ml/minx3CV再生， 20mM 硼砂 /硼酸 _17mM NaCl (pH 9.0， A液） lOml/min洗脱 5CV。 rHuGH的 PEG修饰反应超纯水稀释样按 6ml/min流速上样， A液 10ml/min洗脱至 第 1个峰完全洗出； 换 20mM硼砂 /硼酸- lOOmM NaCl (pH 9.0， B液）， 10ml/min洗脱至第 2个峰完全洗出； 换 20mM硼砂 /硼酸 -200mM NaCl (pH 9.0, C液）， lOml/min洗脱至第 3个峰完全洗出。 洗脱液检测波长 280nm (AKTA Basic 100, GE Healthcare )0收集第 2个峰样品即为目的样。 用 5K超滤器（Millipore, 聚醚砜材质）将目的样的缓冲体系超滤替换成 5mM NaAc/HAc (pH 4.5)。
2.2 MacroCap SP层析纯化
层析柱体（上海锦华层析设备厂）规格为 0>12mmx300mm， MacroCap SP 填料 （GE Healthcare) 装填规格为 O12mmxl80mm， lCV=20ml。 MacroCap SP层析柱用 0.5M NaOH 1 ml/minx 3 Omin在位清洗， ddH20 lml/min洗脱 3CV， 1M NaCl lml/minx3CV再生， 5mM NaAc/HAc(pH 4.5， A液） lml/min洗脱 5CV。 PEG-rHuGH的 Q Sepharose FF层析纯化超滤 替换样 lml/min上样， A液 lml/min洗脱 3CV;换 5mM NaAc/HAc-100mM NaCl (pH 4.5， B液）， 0%- 30%B液 lml/min梯度洗脱 5CV， 30%-45%B 梯度洗脱 10CV; 换 5mM NaAc/HAc- 1M NaCl (pH 4.5, C液）， lml/min 洗脱至第 1、 2峰完全洗出。 洗脱液检测波长 280nm (AKTA Basic 100, GE Healthcare 收集 30%_45%B梯度洗脱时之第 5到第 8个 CV的洗脱 样品即为目的样。 用 5K超滤器 （Millipore, 聚醚砜材质）将目的样的缓 冲体系超滤替换成 3mM NaAc/HAc-7mM NaCl-5mM Lys (pH 5.0)，补力口 甘露醇至终浓度 45mg/ml， 0.2μπι过滤除菌； 取样 SDS-PAGE电泳， 银染 显色； 余样- 70°C冻存， 样品编号： U6-l、 Y6-l。 SDS-PAGE电泳检测结 果示于图 8， SDS-PAGE电泳表观分子量检测结果示于图 9。
PEG-rHuGH各样品上样 10μβ情况下均检出少量多位点修饰物， 各 样品底物蛋白 （rfiuGH) 含量均不超过 0.5% (图 8) ， 主带含量均不低 于 80%。 PEG-rHuGH各样品 SDS-PAGE电泳表观分子量检测结果均为 1 条主带， Y6-1的表观分子量明显大于 Y10.5, U6-1的表观分子量明显大 于 U10.5 (图 9) 。
3、 MALDI-TOF MS分子量检测
采用德国 BRUKER公司 autoflex TOF/TOF质谱仪， MALDI-TOF MS 法测定 PEG-rHuGH各样品的分子量。 检测方法同实施例 3。 结果示于图
Y6-1和 U6-1 的 MS分子量均在 62012道尔顿 ± 10%的范围内， 与 PEG单位点修饰 rHuGH的理论分子量一致 （YPEG-NHS和 UPEG-NHS 的分子量为 40kD± 10%)， 均为 PEG单位点修饰物。
4、 细胞学活性检测
以 GH 国家标准品为对照， 采用 HuGH依赖型大鼠淋巴瘤细胞株 Nb2-11检测 PEG-rHuGH各样品的细胞学活性，比较 Y6-1与 Y10.5、U6-1 与 U10.5的细胞学活性的差别。检测方法同实施例 3。检测结果示于表 3， 每个样品检测 3个平行样。
Y10.5的平均细胞学比活性为 Z.OSxlO^IU/mg, Y6-1的平均细胞学比 活性为 5.50xl(T2IU/mg; U10.5的平均细胞学比活性为 S xlO^IU/mg, U6-1 的平均细胞学比活性为 5.00xlO_2IU/mg。 Y10.5 U10.5的平均细胞学比活 性明显高于 Y6~l/U6-1， 可达后者的 3倍左右。
表 3.YPEG-rHuGH和 UPEG-rHuGH各样品细胞学活性检测结果
Figure imgf000028_0001
注： 1、 以 GH 国家标准品为标准， 标准品批号： 35-20002, lmg ml/支， 3IU/支， 购自中国药品 生物制品检定所。 2、 为 3个平行样检测结果的平均。 实施例 5 YPEG-rHuGH (Y10.5) 和 UPEG-rHuGH (U10.5 ) 的体内生物学
活性检测
以去脑垂体大鼠为动物模型， 按《中国药典》 2005年版附录 ΧΠ P生 长激素生物测定法测定 YPEG-rHuGH (Y10.5)和 UPEG-rHuGH (U10.5 ) 的体内促进动物生长的生物学活性， 即观察一次性给药一周后对去脑垂 体大鼠 （无内源性生长激素） 生长发育作用的影响。
采用 Wistar大鼠， SPF级， 雄性， 出生 26-28d， 体重 60-80g; 由中 国药品生物制品检定所实验动物中心提供， 动物合格证号： SCXK (京） 2005-0004号。 试验前 2-3周无菌条件下手术摘除大鼠脑垂体， 于二级实 验室正常饲养使其恢复备用。 筛选合格去脑垂体大鼠， 按体重均匀分成 10组， 每组 10只， 具体为： 阴性对照（空白溶剂）组； 阳性对照 rHuGH (GH国家标准品， 由中国药品生物制品检定所制备， 规格 3Il mg 支 低 (2.7111-kg-1 ) 、 中 (SJIU-kg 1 ) 、 高 ( 10.7IU.kg-1 ) 剂量组， 分 6次 给药，每日一次，连续 6日；供试品 Y10.5低（2.7IU'kg )、中（SJIU-kg'1 ) 高 ( 10.7IU.kg-1 )剂量组，供试品 U10.5低 (2.7IU-kg 1 )、中 (5.3IU'kg )、 高（lOJIU'kg )剂量组，与标准品给药的第一天同时一次性给药。 Y10.5 和 U10.5按估计效价 3IU/mg配制。 于动物颈部皮下注射给药， 给药容积 0.5ml; 阴性对照组只给予溶剂， 每天给药 1次、 共连续给药 6次。 于阳 性对照组最后 1次给药后 24h处死大鼠， 检测体重和胫骨骨骺板宽度。 按《中国药典》 2005年版附录 ΧΠ P生长激素生物测定法和附录 XIV生物 检定统计法处理数据。
YPEG-rHuGH (Y10.5 ) 的生物效价为 5.0IU'mg ， UPEG-rHuGH (U10.5) 的生物效价为 S^IU.mg-1 , 均为普通 rHuGH的 1.5倍以上。 YPEG-rHuGH (Y10.5 ) 和 UPEG-rHuGH (U10.5 ) 一次给药比需每天注 射给药的 rHuGH具有更高的促进动物机体生长的生物活性和长效的药 理作用。 实施例 6
YPEG-rHuGH (Y10.5 ) 食蟹猴血清药代半衰期检测 选用 6只食蟹猴， 雌 3雄 3， 体重 3.24-5.48 kg (广西北海市玉琦实 验动物科技有限公司， 合格证编号： SCXK (桂） 2005-0005 )。 实验分为 2组，每组 3只食蟹猴，分别为： YPEG-rHuGH(Y10.5 )皮下注射 SOO g'kg—1 ( 只， 早 1 只） 组和 rHuGH (Saizen, 思真； 瑞士雪兰诺大药厂） 皮 下注射 SOO g^g 组（ 1只， 早 2只）； 单次给药。 给药后定时抽取注药 对侧后肢静脉血， 分离血清； 采用 R&D公司的 Human Growth Hormone EUSA试剂盒 ELISA法检测血药浓度， 绘制血药浓度变化曲线， 计算药 代半衰期。 结果示于图 10。
食蟹猴皮下注射 SOO g'kg-1 YPEG-rHuGH (Y10.5 ) 后， 血清药物浓 度达峰时间在 8-24h， 药物消除缓慢； 平均血清药代半衰期为 41.33h。 食 蟹猴皮下注射 SOO g.kg-1 rHuGH (思真） 后， 血清药物浓度达峰时间在 l-2h, 至 24h已降到药前水平， 消除明显快于 YPEG-rHuGH (Y10.5); 平均血清药代半衰期为 1.80h。 YPEG-rHuGH (Y10.5 ) 的平均血清药代 半衰期为 rHuGH的 20倍以上。

Claims

权 利 要 求 书
1、 一种制备聚乙二醇化生长激素的方法， 包括如下步骤：
a)在 pH不低于 6.0、 优选不低于 7.0、 优选不低于 8.0、 优选不低于 9.0、 优选不低于 9.5、 优选不低于 10.0、 最优选为 10.5的溶液中将 U型 或 Y型分支的双链聚乙二醇和生长激素优选人生长激素接触， 优选所述 生长激素和双链聚乙二醇的摩尔比为大约 1 : 2；
b) 在适当浓度的 SDS-PAGE、 优选 12% SDS-PAGE中检测 a) 步骤 所得的聚乙二醇单位点修饰产物， 其中所述产物为两条带；
c) 分离、 回收所述两条带中表观分子量低的聚乙二醇单位点修饰产 物；
任选地还包括纯化步骤， 优选使用凝胶层析方法如 Q Sepharose FF 层析、 DEAE Sepharose FF层析或 MacroCap SP层析纯化。
2、权利要求 1的方法，其中所述双链聚乙二醇为具有如下结构式（I) 的 Y型聚乙二醇，
Figure imgf000031_0001
(I)
其中： P^nPb是相同或不同的聚乙二醇； j 为 1-12 的整数； R^H、 CM2 经取代或未经取代的垸基、 取代芳基、 芳垸基或杂垸基； χ^πχ2分别独 立地是连接基团，其中 X HA, X2为选自于以下组中的基团： (CH2)n, (CH2)nOCO、（CH2)nNHCO、（CH2)nCO， 而 n为 1-10的整数； F 是选自于以 下组中的端基： 羟基、 羧基、 酯基、 酰氯、 酰肼、 马来酰亚胺、 吡啶二 硫化物， 可以与治疗药物或基体上的氨基、 羟基或硫羟基反应形成共价 键。
3、权利要求 2的方法，其中所述 Y型聚乙二醇具有如下结构式（II):
Figure imgf000032_0001
(II)
其中 R和 R，为无关的低分子量垸基， 优选 -C4垸基， 最优选甲基； m 和 m，表征聚合度， 为任何整数； m+m'优选 600到 1500， 最优选 910。
4、权利要求 3的方法，其中所述 Y型聚乙二醇具有如下结构式（III):
Figure imgf000032_0002
(III)
其中优选聚乙二醇的总平均分子量为约 26 kD至 60 kD, 优选为 40 kD。
5、权利要求 1的方法，其中所述双链聚乙二醇为具有如下结构式 (IV) 的 U型聚乙二醇，
Figure imgf000032_0003
(IV)
其中 R和 R，为独立无关的低分子量垸基， 优选 d-C4烷基； n和 n'表征 聚合度， 为任何整数； n+n，介于 600-1500之间， 最优选 910; 所述 U型 聚乙二醇平均分子量为约 26kD至 66 kD， 最优选为约 40 kD。
6、 权利要求 4的方法， 其包括如下步骤：
a) 在 pH 9.0或 10.5的溶液中将下式 （III) 所示的聚乙二醇和人生 长激素接触，其中所述人生长激素和双链聚乙二醇的摩尔比为大约 1 : 2；
Figure imgf000033_0001
(III)
其中 m+m，为 910， 聚乙二醇的总平均分子量为约 40 kD;
b)在 12% SDS-PAGE中检测 a) 步骤中所得的聚乙二醇单位点修饰 产物， 其中所述产物为以表观分子量低的条带为主；
c) 使用凝胶层析方法分离、 回收所述表观分子量低的聚乙二醇单位 点修饰产物； 所述凝胶层析方法选自 Q Sepharose FF 层析、 DEAE Sepharose FF层析或 MacroCap SP层析。
7、 用权利要求 1-6任一项的方法制备的聚乙二醇化生长激素， 其中 所述生长激素为从天然来源提取的或通过重组生物技术获得的重组生长 激素， 优选具有 SEQ ID NO: 1所示序列。
8、 权利要求 7的聚乙二醇化生长激素， 其分子量为 62kD， 如下式 (VII) 所示：
Figure imgf000033_0002
(VII)
其中 R和 R'为无关的低分子量烷基，优选 C C4垸基，最优选甲基； m+m' 为 910; j 为 1-12的整数。
9、 一种制备聚乙二醇化生长激素制备物的方法， 包括如下步骤： a)在 pH不低于 8.0、 优选不低于 9.0、 优选不低于 9.5、 优选不低于
10.0、 最优选为 10.5的溶液中将 U型或 Y型分支的双链聚乙二醇和生长 激素优选人生长激素接触， 优选所述生长激素和双链聚乙二醇的摩尔比 为大约 2；
b) 在适当浓度的 SDS-PAGE、 优选 12% SDS-PAGE中检测 a) 步骤 所得的聚乙二醇单位点修饰产物， 其中所述产物为两条带；
c) 分离、 回收所述聚乙二醇单位点修饰产物；
所述回收的产物是以表观分子量低的聚乙二醇单位点修饰产物为主 的混合物， 其中表观分子量低的聚乙二醇单位点修饰产物的 SDS-PAGE 含量不低于 70%、 优选不低于 80%、 最优选不低于 90%，
任选地还包括纯化步骤， 优选使用凝胶层析方法如 Q Sepharose FF 层析、 DEAE Sepharose FF层析或 MacroCap SP层析纯化。
10、 权利要求 9 的方法， 其中所述双链聚乙二醇为具有如下结构式
(I) 的 Y型聚乙二醇，
Figure imgf000034_0001
(I)
其中： P^Pb是相同或不同的聚乙二醇； j 为 1-12 的整数； Ri H、 C1-12 经取代或未经取代的垸基、 取代芳基、 芳垸基或杂垸基； X^BX2分别独 立地是连接基团，其中 X^(CH2)n， X2为选自于以下组中的基团： (CH2)n, (CH2)nOCO、（CH2)nNHCO、 (CH2)nCO, 而 n为 1-10的整数； F 是选自于以 下组中的端基： 羟基、 羧基、 酯基、 酰氯、 酰肼、 马来酰亚胺、 吡啶二 硫化物， 可以与治疗药物或基体上的氨基、 羟基或硫羟基反应形成共价
11、 权利要求 10的方法， 其中所述 Y型聚乙二醇具有如下结构式 (II): ROCH2CH2(OCH2CH2 )m-0- CH2CH2,
N_(CHR 厂 F
R'。CH2 CH2(OCH2 CH2)m'—o— CH，一 C
' II
o
(II)
其中 R和 R，为无关的低分子量垸基， 优选 CrC4烷基， 最优选甲基； m 和 m，表征聚合度， 为任何整数； m+m，优选 600到 1500， 最优选 910。
12、 权利要求 11 的方法， 其中所述 Y型聚乙二醇具有如下结构式
Figure imgf000035_0001
(III)
其中优选聚乙二醇的总平均分子量为约 26 kD至 60 kD, 优选为 40 kD。
13、 权利要求 9的方法， 其中所述双链聚乙二醇为具有如下结构式
(IV) 的 U型聚乙二醇，
Figure imgf000035_0002
(IV)
其中， R和 R，为独立无关的低分子量烷基， 优选 d-C4烷基； n和 n'表征 聚合度， 为任何整数； n+n，介于 600-1500之间， 最优选 910; 所述 ϋ型 聚乙二醇平均分子量为约 26kD至 66 kD， 最优选为约 40 kD。
14、 权利要求 12的方法， 其包括如下步骤：
a) 在 pH 9.0或 10.5的溶液中将下式 （ΠΙ) 所示的聚乙二醇和人生 长激素接触， 其中所述人生长激素和双链聚乙二醇的摩尔比为大约 1 : 2；
Figure imgf000036_0001
(III)
其中 m+m'为 910， 聚乙二醇的总平均分子量为约 40 kD;
b)在 12% SDS-PAGE中检测 a) 步骤中所得的聚乙二醇单位点修饰 产物；
c) 使用凝胶层析方法分离、 回收所述聚乙二醇单位点修饰产物， 所 述凝胶层析方法选自 Q Sepharose FF层析、 DEAE Sepharose FF层析或 MacroCap SP层析，所述回收的产物中表观分子量低的聚乙二醇单位点修 饰产物的 SDS-PAGE含量不低于 70%、 优选不低于 80%、 最优选不低于 9。o/0。
15、 用权利要求 9-14任一项的方法制备的聚乙二醇化生长激素制备 物， 其中所述生长激素为从天然来源提取的或通过重组生物技术获得的 重组生长激素， 优选具有 SEQ ID NO: 1所示序列。
16、 权利要求 15的聚乙二醇化生长激素制备物， 其中所述聚乙- 单位点修饰产物如下式 （VII) 所示：
Figure imgf000036_0002
(VII)
其中 R和 R'为无关的低分子量垸基，优选 d-C^垸基，最优选甲基； m+m' 为 910; j 为 1-12的整数，所述聚乙二醇化生长激素制备物中表观分子量 低的聚乙二醇单位点修饰产物的 SDS-PAGE含量不低于 70%、 优选不低 于 80°/。、 最优选不低于 90%。
17、 权利要求 7或 8的聚乙二醇化生长激素或者权利要求 15或 16 的聚乙二醇化生长激素制备物， 其中所述重组生长激素是人工合成的或 由选自如下一组的表达系统表达： 原核系统如大肠杆菌； 真核酵母系统 如毕赤酵母； 昆虫细胞系统； 和哺乳动物细胞系统如 CHO细胞。
18、 一种组合物， 其包含药物学有效剂量的权利要求 7、 8、 15-17 任一项的聚乙二醇化生长激素或聚乙二醇化生长激素制备物和药物学可 接受的载体或赋形剂， 优选包含甘露醇、 氨基酸、 氯化钠、 醋酸和醋酸 钠， 其中氨基酸优选天冬氨酸、 天冬酰氨、 赖氨酸和甘氨酸。
19、权利要求 7、 8、 15-17任一项的聚乙二醇化生长激素或聚乙二醇 化生长激素制备物或权利要求 18的组合物在制备用于治疗需要用生长激 素治疗的疾病和抗衰老治疗的药物中的应用， 所述需要用生长激素治疗 的疾病优选选自矮小症、烧伤、创伤、骨折、出血性溃疡、肾衰竭、 AIDS. 内源性生长素缺乏性矮小症、 Turner综合症、 合成代谢障碍和成人生长 激素缺乏。
20、 一种治疗患有需要用生长激素治疗的疾病的患者和抗衰老治疗 的方法， 所述方法包括给予所述患者治疗有效量的权利要求 7、 8、 15-17 任一项的聚乙二醇化生长激素或聚乙二醇化生长激素制备物或权利要求 18的组合物， 其中所述需要用生长激素治疗的疾病优选选自矮小症、 烧 伤、 创伤、 骨折、 出血性溃疡、 肾衰竭、 AIDS、 内源性生长素缺乏性矮 小症、 Turner综合症、 合成代谢障碍和成人生长激素缺乏。
PCT/CN2008/000674 2008-04-03 2008-04-03 双链聚乙二醇修饰的生长激素及其制备方法和应用 WO2009121210A1 (zh)

Priority Applications (15)

Application Number Priority Date Filing Date Title
EP08733888.5A EP2272875B1 (en) 2008-04-03 2008-04-03 Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
US12/936,164 US9840546B2 (en) 2008-04-03 2008-04-03 Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
JP2011502208A JP5458416B2 (ja) 2008-04-03 2008-04-03 二本鎖ポリエチレングリコール化成長ホルモン、その製造方法およびその使用
MX2010010953A MX2010010953A (es) 2008-04-03 2008-04-03 Hormona de crecimiento modificada con glicol de polietileno de doble cadena, metodo de preparacion y aplicación del a misma.
CN200880009718XA CN101809038B (zh) 2008-04-03 2008-04-03 双链聚乙二醇修饰的生长激素及其制备方法和应用
DK08733888.5T DK2272875T3 (da) 2008-04-03 2008-04-03 Dobbeltstrenget polyethylenglycolmodificeret væksthormon, fremstillingsmetode samt anvendelse deraf
PT87338885T PT2272875E (pt) 2008-04-03 2008-04-03 Hormona de crescimento modificada com polietilenoglicol de cadeia dupla, método de preparação e aplicação deste
CA2720306A CA2720306C (en) 2008-04-03 2008-04-03 Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
AU2008353850A AU2008353850B2 (en) 2008-04-03 2008-04-03 Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
RU2010136327/10A RU2488598C2 (ru) 2008-04-03 2008-04-03 Гормон роста, модифицированный двухцепочечным полиэтиленгликолем, способ его получения и применение
KR1020107022013A KR101521674B1 (ko) 2008-04-03 2008-04-03 이중-가닥 폴리에틸렌 글리콜-수식된 성장 호르몬, 이의 제조 방법 및 용도
PCT/CN2008/000674 WO2009121210A1 (zh) 2008-04-03 2008-04-03 双链聚乙二醇修饰的生长激素及其制备方法和应用
PL08733888T PL2272875T3 (pl) 2008-04-03 2008-04-03 Hormon wzrostu modyfikowany dwuniciowym glikolem polietylenowym, sposoby otrzymywania i stosowania
ES08733888.5T ES2453946T3 (es) 2008-04-03 2008-04-03 Hormona del crecimiento modificada con polietilenglicol bicatenario, método de preparación y aplicación de esta
BRPI0822530-3A BRPI0822530B1 (pt) 2008-04-03 2008-04-03 Método de preparação de um hormônio de crescimento humano glicolado por polietileno (modificado por peg), hormônio do crescimento humano modificado por peg de menor peso molecular aparente e seu uso, preparação de hormônio do crescimento humano modificado por peg de menor peso molecular aparente e seu método de preparação e composição

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2008/000674 WO2009121210A1 (zh) 2008-04-03 2008-04-03 双链聚乙二醇修饰的生长激素及其制备方法和应用

Publications (1)

Publication Number Publication Date
WO2009121210A1 true WO2009121210A1 (zh) 2009-10-08

Family

ID=41134798

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2008/000674 WO2009121210A1 (zh) 2008-04-03 2008-04-03 双链聚乙二醇修饰的生长激素及其制备方法和应用

Country Status (15)

Country Link
US (1) US9840546B2 (zh)
EP (1) EP2272875B1 (zh)
JP (1) JP5458416B2 (zh)
KR (1) KR101521674B1 (zh)
CN (1) CN101809038B (zh)
AU (1) AU2008353850B2 (zh)
BR (1) BRPI0822530B1 (zh)
CA (1) CA2720306C (zh)
DK (1) DK2272875T3 (zh)
ES (1) ES2453946T3 (zh)
MX (1) MX2010010953A (zh)
PL (1) PL2272875T3 (zh)
PT (1) PT2272875E (zh)
RU (1) RU2488598C2 (zh)
WO (1) WO2009121210A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107446908A (zh) * 2016-06-01 2017-12-08 湖南华腾制药有限公司 分支型聚乙二醇修饰的l‑门冬酰胺酶及其制备方法
US9840546B2 (en) 2008-04-03 2017-12-12 Biosteed Gene Expression Tech. Co., Ltd. Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10047623B2 (en) * 2014-12-17 2018-08-14 United Technologies Corporation Compliant seal assembly and method of operating
CN114539384B (zh) * 2020-11-19 2024-09-06 江苏众红生物工程创药研究院有限公司 聚乙二醇化长效生长激素及其制备方法和医药应用
CN114740108B (zh) * 2022-03-28 2023-07-14 天津键凯科技有限公司 一种聚合物修饰抗体类药物的修饰度的测定方法
CN115845079B (zh) * 2022-11-24 2023-07-18 武汉禾元生物科技股份有限公司 一种重组人血清白蛋白与重组人生长激素的偶联物及其制备方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0593868A1 (en) 1992-08-26 1994-04-27 F. Hoffmann-La Roche Ag PEG-interferon conjugates
EP0809996A2 (en) 1996-05-31 1997-12-03 F. Hoffmann-La Roche Ag Interferon conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6342375B1 (en) * 1996-10-24 2002-01-29 Universidad Autonoma De Nuevo Leon Modified methylotrophic Pichia pastoris yeast which secretes human growth hormone
WO2003076490A1 (fr) * 2002-03-13 2003-09-18 Beijing Jiankai Technology Co., Ltd. Derive polymere hydrophile a ramification de type y et procede de preparation d'un composite medical contenant le compose precite
CN1477126A (zh) 2002-07-22 2004-02-25 长春金赛药业有限责任公司 长效生长激素及药物组合物
US20040223950A1 (en) 2002-11-15 2004-11-11 Doris Brugger Positional isomers of pegylated alpha interferon
CN1608079A (zh) * 2001-11-20 2005-04-20 法玛西雅公司 化学修饰的人生长激素缀合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2158603C2 (ru) * 1994-05-31 2000-11-10 Амген Инк. Способы и препараты для стимулирования роста и дифференцировки мегакариоцитов
JP4593048B2 (ja) * 1999-12-24 2010-12-08 協和発酵キリン株式会社 分岐型ポリアルキレングリコール類
MXPA04004336A (es) * 2001-11-07 2005-05-16 Nektar Therapeutics Al Corp Polimeros ramificados y sus conjugados.
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
WO2006094530A1 (en) * 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
US20060233740A1 (en) * 2005-03-23 2006-10-19 Bossard Mary J Conjugates of an hGH moiety and a polymer
EP2236521A4 (en) * 2007-12-29 2013-07-10 Biosteed Gene Expression Tech Co Ltd BY POLYETHYLENE GLYCOL OF Y-TYPE MODIFIED G-CSF AND METHOD FOR THE PRODUCTION AND USE THEREOF
EP2272875B1 (en) 2008-04-03 2014-01-15 Biosteed Gene Expression Tech. CO., LTD. Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0593868A1 (en) 1992-08-26 1994-04-27 F. Hoffmann-La Roche Ag PEG-interferon conjugates
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
EP0809996A2 (en) 1996-05-31 1997-12-03 F. Hoffmann-La Roche Ag Interferon conjugates
US6342375B1 (en) * 1996-10-24 2002-01-29 Universidad Autonoma De Nuevo Leon Modified methylotrophic Pichia pastoris yeast which secretes human growth hormone
CN1608079A (zh) * 2001-11-20 2005-04-20 法玛西雅公司 化学修饰的人生长激素缀合物
WO2003076490A1 (fr) * 2002-03-13 2003-09-18 Beijing Jiankai Technology Co., Ltd. Derive polymere hydrophile a ramification de type y et procede de preparation d'un composite medical contenant le compose precite
EP1496076A1 (en) 2002-03-13 2005-01-12 Beijing Jiankai Technology Co., Ltd. Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound
CN1243779C (zh) 2002-03-13 2006-03-01 北京键凯科技有限公司 具有y形分支的亲水性聚合物衍生物、其制备方法、与药物分子的结合物以及包含该结合物的药物组合物
CN1477126A (zh) 2002-07-22 2004-02-25 长春金赛药业有限责任公司 长效生长激素及药物组合物
US20040223950A1 (en) 2002-11-15 2004-11-11 Doris Brugger Positional isomers of pegylated alpha interferon

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
"Appendix XII P", PHARMACOPOEIA OF THE PEOPLE'S REPUBLIC OF CHINA, vol. 3, 2005
CHAMOW ET AL.: "MODIFICATION OF CD4 IMMUNOADHESIN WITH MONOMETHOXYPOLY(ETHYLENE GLYCOL) ALDEHYDE VIA REDUCTIVE ALKYLATION", BIOCONJ. CHEM., vol. 5, no. 2, 1994, pages 133 - 140, XP000434384, DOI: doi:10.1021/bc00026a005
CHEN E Y ET AL.: "The human growth hormone locus: nucleotide sequence, biology and evolution", GENOMICS, vol. 4, 1989, pages 479 - 497, XP024797988, DOI: doi:10.1016/0888-7543(89)90271-1
DELGADO ET AL.: "THE USES AND PROPERTIES OF PEG-LINKED PROTEINS", CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, vol. 9, 1992, pages 249 - 304, XP002930070
DENOTO F M ET AL.: "Human growth hormone DNA sequence and mRNA structure: possible alternative splicing", NUCLEIC ACIDS RES., vol. 9, 1981, pages 3719 - 3730, XP000616072
IGLESIAS P ET AL.: "Recombinant human growth hormone therapy in malnourished dialysis patients: a randomized controlled study", AM. J. KIDNEY DIS., vol. 32, no. 3, 1998, pages 454 - 463, XP028841229, DOI: doi:10.1053/ajkd.1998.v32.pm9740162
INADA ET AL.: "POLYETHYLENE GLYCOL(PEG)-PROTEIN CONJUGATES: APPLICATION TO BIOMEDICAL AND BIOTECHNOLOGICAL PROCESSES", J. BIOACT. AND COMPATIBLE POLYMERS, vol. 5, 1990, pages 343 - 364, XP001008119
INOUE ET AL.: "A HIGHLY ENHANCED THROMBOPOIETIC ACTIVITY BY MONOMETHOXY POLYETHYLENE GLYCOL-MODIFIED RECOMBINANT HUMAN INTERLEUKIN-6", J. LAB. CLIN. MED., vol. 124, no. 4, 1994, pages 529 - 536
KATRE ET AL.: "Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model", PROC. NATL. ACAD. SCI. USA, vol. 84, no. 6, 1987, pages 1487 - 1491, XP055272577, DOI: doi:10.1073/pnas.84.6.1487
KATRE: "The conjugation of proteins with polyethylene glycol and other polymers. Altering properties of proteins to enhance their therapeutic potential", ADVANCED DRUG DELIVERY SYSTEMS, vol. 10, 1993, pages 91 - 114, XP002084717, DOI: doi:10.1016/0169-409X(93)90005-O
MARTIAL J A ET AL.: "Human growth hormone: Complementary DNA cloning and expression in bacteria", SCIENCE, vol. 205, 1979, pages 602 - 607, XP008045809, DOI: doi:10.1126/science.377496
NEELY E K: "Use and abuse of human growth hormone", ANNU. REV. MED., vol. 45, 1994, pages 407 - 410
PHARMACOPOEIA OF THE PEOPLE'S REPUBLIC OF CHINA, 2005
PHARMACOPOEIA OF THE PEOPLE'S REPUBLIC OF CHINA, vol. 2, 2005
ROSKAM W ET AL.: "Molecular cloning and nucleotide sequence of the human growth hormone structural gene", NUCLEIC ACIDS RES., vol. 7, 1979, pages 305 - 320
ROSS CLARK; KENNETH OLSON ET AL.: "Long-acting growth hormones produced by conjugation with polyethylene glycol", J. BIOL. CHEM., vol. 271, 1996, pages 21969 - 21977
SATAKE-ISHIKAWA ET AL.: "CHEMICAL MODIFICATION OF RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR BY POLYETHYLENE GLYCOL INCREASES ITS BIOLOGICAL ACTIVITY IN VIVO", CELL STRUCTURE AND FUNCTION, vol. 17, no. 3, 1992, pages 157 - 160, XP008037990
See also references of EP2272875A4
TSUTSUMI ET AL.: "CHEMICAL MODIFICATION OF NATURAL HUMAN TUMOR NECROSIS FACTOR-APHA WITH POLYETHYLENE GLYCOL INCREASES ITS ANTI-TUMOR POTENCY", JPN. J. CANCER RES., vol. 85, no. 1, 1994, pages 9 - 12, XP002913448
YU-SEN WANG ET AL.: "Identification of the Major Positional Isomer of Pegylated Interferon Alpha-2b", BIOCHEMISTRY, vol. 39, no. 35, 2000, pages 10634 - 10640
YU-SEN WANG ET AL.: "Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications", ADVANCED DRUG DELIVERY REVIEWS, vol. 54, no. 4, 2002, pages 547 - 570, XP002989691, DOI: doi:10.1016/S0169-409X(02)00027-3

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840546B2 (en) 2008-04-03 2017-12-12 Biosteed Gene Expression Tech. Co., Ltd. Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
CN107446908A (zh) * 2016-06-01 2017-12-08 湖南华腾制药有限公司 分支型聚乙二醇修饰的l‑门冬酰胺酶及其制备方法

Also Published As

Publication number Publication date
DK2272875T3 (da) 2014-03-31
EP2272875B1 (en) 2014-01-15
RU2488598C2 (ru) 2013-07-27
ES2453946T3 (es) 2014-04-09
PT2272875E (pt) 2014-04-28
RU2010136327A (ru) 2012-05-10
CN101809038B (zh) 2013-10-30
US9840546B2 (en) 2017-12-12
MX2010010953A (es) 2011-04-21
AU2008353850A1 (en) 2009-10-08
CA2720306A1 (en) 2009-10-08
BRPI0822530A2 (pt) 2020-08-18
US20110028388A1 (en) 2011-02-03
JP5458416B2 (ja) 2014-04-02
AU2008353850B2 (en) 2014-08-21
KR101521674B1 (ko) 2015-05-19
KR20110014564A (ko) 2011-02-11
EP2272875A4 (en) 2011-08-31
PL2272875T3 (pl) 2014-06-30
JP2011516429A (ja) 2011-05-26
EP2272875A1 (en) 2011-01-12
BRPI0822530B1 (pt) 2022-03-22
CA2720306C (en) 2016-03-15
CN101809038A (zh) 2010-08-18

Similar Documents

Publication Publication Date Title
JP5407044B2 (ja) インターフェロンα変異体およびそのポリエチレングリコール誘導体
RU2485134C2 (ru) Интерферон альфа 2в, модифицированный полиэтиленгликолем, получение препарата и его применение
JP2008509889A (ja) ペグ化インターフェロンα−１ｂ
KR100694994B1 (ko) 사람 과립구 콜로니 형성인자 동종체
WO2009121210A1 (zh) 双链聚乙二醇修饰的生长激素及其制备方法和应用
WO2009086656A1 (zh) Y型聚乙二醇修饰的g-csf及其制备方法和应用
KR101483814B1 (ko) 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2ａ, 이의 합성 방법 및 용도
KR101104574B1 (ko) 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도
WO2006116948A1 (fr) Conjugue de polyethylene glycol et d’interleukine-6 et son procede de preparation et son utilisation
KR20080041661A (ko) 생체적합성 폴리머와 컨쥬게이트된 인간 성장 호르몬
CN111484551B (zh) 一种聚乙二醇修饰的重组人碱性成纤维细胞生长因子
US20060134736A1 (en) Human growth hormone conjugated with biocompatible polymer
CN114920819A (zh) 重组人生长激素突变体、其聚乙二醇衍生物、聚乙二醇衍生物的制备方法及其药物用途

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880009718.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08733888

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2011502208

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 20107022013

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12936164

Country of ref document: US

Ref document number: 2008353850

Country of ref document: AU

Ref document number: 2720306

Country of ref document: CA

Ref document number: 2008733888

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/010953

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008353850

Country of ref document: AU

Date of ref document: 20080403

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010136327

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0822530

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20101004